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INTRODUCTION
1INTRODUCTION
India  is  a  vast  country  with  more  than  one  billion  people  and  spread  over  an
area of 3.3 thousand million square kilometers [1,2]. The geographical and
environmental conditions vary in different places of the country. Located in the tropics
with heavy annual monsoon, the climatic conditions are favorable  for the fungi to grow
in  many  parts  of  the  country.  All  of  these  factors  together  favour  widespread
occurrence of both common and unique mycotic infections. Invasive fungal infections
(IFIs) have shown a steady rise in incidence among  immunocompromised and
critically ill patients in whom they are the major cause of morbidity and mortality [3,4].
The precise prevalence of disease is not known but population-based surveillance
estimates it as 12–17 per 100 000 population [4,5,6].
Several reasons favoring IFIs include usage of anti neoplastic and
immunosuppressive agents, broad-spectrum antibiotics, patients with uncontrolled
diabetes mellitus, burns, neutropenia, HIV infection, prolonged intensive care unit
(ICU) admission and aggressive surgery[7].
The frequency of IFI is 5-30% in patients with malignancy[3,8] , 2-42% in organ
transplant recipients,20-25% among AIDS patients and 10-15% among Diabetes
mellitus (DM) patients[3,9].
In India about 30million people are affected by diabetes mellitus and
3-6million people have HIV infection [10] . Solid organ transplantation are performed
increasingly in tertiary care centers. Systemic steroids, immunosuppressive agents and
chemotherapeutic agents are available all over the country for prevention of transplant
rejection and for treatment of malignancy.
2The diagnosis of IFI rests on a combination of clinical and laboratory
parameters. Many of the suspected IFI are not proven. Slow growth of certain fungi
such as dematiaceous fungi often causes delay in clinching the diagnosis. The exact
incidence of opportunistic IFI is not known due to fewer diagnostic mycology
laboratories. Most clinicians are unaware of manifestations of mycotic diseases. Only a
handful of centers carry out routine medical autopsies. Thus, our knowledge about
these diseases is just the tip of a huge iceberg [1].
Candida spp and Aspergillus spp are the most common etiological agents of
invasive fungal infections[11-16]. The estimated annual incidence of invasive mycoses
due to these pathogens is 72–228 infections per million population for Candida spp and
12–34 infections per million population for Aspergillus spp [17-23]. Cryptococcus spp is
the most common isolate from AIDS patients[7]  and those on corticosteriods in whom it
causes pneumonia and meningitis with annual incidence of 30–66 infections per million
population [17-23].
Zygomycetes are more common among  patients with uncontrolled diabetes
mellitus and those on iron therapy [24]. Fusarium spp, Penicillium spp and dematiaceous
fungi are also reported among immunosuppressed patients [7].
Accurate diagnosis of invasive fungal infection remains a problem in
immunocompromised patients, in whom signs and symptoms are nonspecific or
develop  late  in  the  course  of  illness  due  to  the  defective  immune  response [4]. Thus,
early diagnosis and prompt initiation of antifungal therapy are essential to reduce
morbidity and mortality [11].
3Antifungal drugs are the mainstay for management of IFI, which are in a
continuum[11]. They are:
? Prophylaxis (administration of antifungal drugs to high-risk groups without
evidence of disease)
? Empirical (administration of  drugs to neutropenic patients with persistent
refractory fever)
? Preemptive (antifungals used using clinical, radiological and laboratory markers
to determine the likelihood of disease)  and
?  Treatment of established fungal infection.
Treatment  may be  prolonged  for  IFI  and  is  often  associated  with  drug  toxicities.
The high cost, limited availability, poor compliance are factors favouring  emergence of
antifungal resistance especially in the settings of immunosuppression [4].
As antifungal susceptibility testing is labour intensive and expensive it is not
routinely performed in all laboratories. The treatment therefore rests on empirical
antifungal therapy with no available data on antifungal susceptibility testing and no
monitoring on emergence of antifungal resistance.
As few data are available in Indian literature on IFI, this study was undertaken.
The etiological agents, the antifungal susceptibility pattern, the risk factors and
categorization of IFI are studied.
AIM OF THE STUDY
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The present study was undertaken with the following aims and objectives.
? To isolate the fungi causing Invasive fungal infections
? To identify and speciate the fungi isolated
? To Identify the common fungal infections occurring in the study among patients
with invasive fungal infections
? To categorize the type of  Invasive fungal infections
? To study the morbid risk factor of  Invasive fungal infections
? To assess the mortality rate among Invasive fungal infection patients
? To study the susceptibility pattern of the fungal isolates to standard anti fungal
drugs
? To compare the different methods of antifungal susceptibility testing done for
the fungal isolates
REVIEW OF LITERATURE
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Among the opportunistic infections, fungal infections have emerged as an
important etiological agent. The fungal infections are now recognised as one of the
significant causes of morbidity and mortality among the human beings. Invasive fungal
infections were regarded as rare disease about a few decades ago. Since then there has
been a steady increase in the number of patients suffering from life threatening fungal
infections. Opportunistic fungal infection is a frequently encountered complication
especially in immune compromised patients like patients suffering from Cancer [25,26] ,
HIV, DM [27,28] etc. The overall incidence of invasive mycosis has been increased from
3% to 30% in of various institutions.
The systematic study of these organisms is about 150 years old. [29]In the past
the fungi have caused only a small proportion of infectious disease, but with increasing
control of infections due to bacteria and viruses through sanitation, education,
immunization and chemotherapy, the fungal infections are becoming more
important.[30]
The fungi are eukaryotic with a range of internal membrane system, membrane
bound organelles and a well defined cell wall. They differ from bacteria in that they
have multilayered cell wall containing chitin, mannan and other polysaccharides and
peptides. The cytoplasm has sterols. The contents of the cytoplasm include
mitochondria, endoplasmic reticulum etc. The nucleus has nuclear membrane and
paired chromosomes and the mode of reproduction is both sexual and asexual resulting
in spore formation[29].
6In 1969, R.H. Whittaker gave an independent status to the fungi in a separate
kingdom [31]. The current classification scheme follows that proposed by Whittaker et
al.  and modified by Morgulis and Schwartz et al. The classification of fungi is based
primarily on the morphology, method of sexual and asexual reproduction [32].
Depending on the cell morphology they are classified into:
1. Yeasts: Unicellular fungi which occur mainly as single, spherical and
ellipsoidal cells which reproduce by budding. eg., Cryptococcus neoformans.
2. Yeast like fungi: Grow partly as yeasts and partly as long filamentous cells
joined end to end forming a pseudo mycelium. eg., Candida albicans.
3. Moulds: Grow as long filaments or hyphae which branch and interlace to form
a meshwork or mycelium and reproduce by formation of various kinds of
spores. eg., Aspergillus spp, Mucor spp, etc.
4. Dimorphic fungi: Grow either as filaments or yeasts according to the cultural
conditions. Mycelial form of growth occurs on culture media at 220C and yeast
form of growth occurs at 370C either on media or in animal body. eg.,
Histoplasma capsulatum.
The systematic classification of the fungi is based on the nature of their sexual
reproduction [33].
1) PHYCOMYCETS: Form usually non septate hyphae and asexual
sporangiospores contained within swollen spore case or sporangium
borne at the ends of aerial hyphae.
72) ASCOMYCETE: Form septate hyphae and various kinds of asexual
spores including conidia.  Sexual ascospores are formed within a sac or
ascus.
3) BASIDIOMYCETES: Form septate hyphae and sexual basidiospores
usually four in number from the ends of the club shaped structure called
basidia.
4) FUNGI IMPERFECTI: Include all those of which the sexual or perfect
state has not been described and which therefore cannot be placed with
certainly in one of the other three classes. A majority of pathogenic
fungi belong to this group.
Very few fungi are capable of causing significant disease in otherwise normal
individuals and the others are only able to produce disease under unusual circumstances
mostly involving host debilitation. The incidence of fungal infections has increased to a
great extent especially among the immune compromised individuals.
The term immune compromised host is defined as a person with impaired host
defense mechanisms and who is at risk of developing an infection. The immune
deficiency may be either as primary or congenital immune deficiency diseases such as
severe combined immunodeficiency, thymic aplasia or other immunoglobulin
deficiencies, and acquired immune deficiency disorders like AIDS, patients with
autoimmune diseases being treated with corticosteroids or cytotoxic therapy, patients
with diabetes mellitus, severe burns, prolonged antibiotic therapy etc. [34].
8CATEGORISATION OF INVASIVE FUNGAL INFECTION
Standard definitions for IFIs was developed by European Organization for
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and
the National Institute of Allergy and Infectious Diseases Mycoses Study Group in 2008
into 3 levels[39] .
They are:
? Proven IFI
? Probable IFI
? Possible  IFI
Three elements which form the basis for categorizing them are[39-41]:
? Host factors,
? Clinical manifestations
? Mycological results.
9PROVEN INVASIVE FUNGAL INFECTIONS
Deep tissue infections
Moulds
? Histo/cytochemistry and/or KOH
showing hyphae from a biopsy or
needle aspiration
OR
? Positive  culture  from  a  normally
sterile site and clinically or
radiologically abnormal site
consistent with infection, obtained
by a sterile procedure
Yeasts
? Histo/cytochemistry showing yeast
cells and/or pseudohyphae from a
biopsy or needle aspiration
excluding mucous membranes
OR
? Positive culture obtained by a
sterile procedure from a normally
sterile site and clinically or
radiologically abnormal site
consistent with infection,
excluding urine, sinuses, and
mucous membranes
OR
? India ink or antigen positivity for
Cryptococcus in CSF
Fungemia
Moulds
? Positive blood culture of fungi
excluding Aspergillus sp and
Penicillium sp, other than
P.marneffei, accompanied by
clinical manifestations compatible
with the relevant organism.
Yeasts
? Positive blood culture of Candida
and other yeasts in patients with
clinical manifestations compatible
with the relevant organism.
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PROBABLE INVASIVE FUNGAL INFECTIONS:
To define probable IFI, it needs atleast one criterion from each of the 3 elements.
? Host section
?  Microbiological criterion
? One major (or two minor) clinical criteria
POSSIBLE INVASIVE FUNGAL INFECTIONS:
? One criterion from host section
? One microbiological OR one major (or two minor) clinical criteria from an
abnormal site consistent with infection
ELEMENTS USED FOR DEFINING IFI:
Host factors
? Neutropenia (<500 neutrophils/mm3 for >10 days)
? Persistent fever for >72 h refractory to appropriate treatment with broad-
spectrum antibacterial  drugs in high-risk patients
? Body temperature of  >380C or <360C
? Recent usage of immunosuppressive agents for more than 30 days
? Previous episode of proven or probable invasive fungal infection in neutropenic
patients
11
? AIDS patients
? Signs and symptoms indicating severe (grade 2) graft-versus-host disease
? Prolonged (>3 weeks) usage of corticosteroids for more than 60 days.
Microbiological criterion
? Positive culture for mould (including Aspergillus, Fusarium, or Scedosporium
spp or  Zygomycetes)  or Cryptococcus neoformans from sputum or
bronchoalveolar lavage fluid samples.
? Positive findings of cytologic/direct microscopic evaluation for mould or
Cryptococcus spp from sputum or bronchoalveolar lavage fluid samples.
? Positive result for Cryptococcal antigen in blood sample.
? Positive findings of cytologic or direct microscopic examination for fungal
elements in sterile body fluid samples (e.g., Cryptococcus species in CSF).
? Two positive reports of culture for yeasts from urine samples in absence of
urinary catheter
? Positive result for Candida sp from blood culture.
? Pulmonary abnormality and negative  bacterial cultures from specimen related
to lower respiratory tract infection
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CLINICAL CRITERIA
Lower Respiratory Tract Infection
Major Minor
Any one of the following new infiltrates
on CT imaging:
? halo sign,
? air crescent sign, or
? cavity within an area of
consolidation
? Symptoms of LRTI (cough, chest
pain, hemoptysis, dyspnea)
? Physical finding of pleural rub
? Any new infiltrate not fulfilling
major criterion
Central Nervous System Infection
Major Minor
Suggestive radiologic evidence of CNS
infection (i.e. meningitis extending from a
paranasal, auricular, or vertebral
process;intracerebral abscesses or infarcts)
(CSF negative for pathogens by culture &
microscopy)
1. Focal neurologic signs and symptoms
2. Mental changes
3. Meningeal irritation
 4. Abnormalities in CSF biochemistry &
cell count
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EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS:
The fungi are widely found in the environment worldwide. Out of 1.5 million
species of fungi estimated to exist all over the world, one third of them 27,000 species
exist in India[42].
Invasive candidiasis
Candida spp is  a  normal  commensal  of  skin,  and  gastrointestinal  and
genitourinary tracts. Candidiasis has no geographic limitation. Previously considered
as commensals but now emerged as opportunistic pathogens causing severe infection
and therapeutic problem.
Candida spp are the most frequent cause of fungal infections (70 to 90% of
cases) and account for 5 to 15% of health-care associated infections[11,43,44].
Candidemia, one of the most frequent clinical manifestations of candidiasis, is
associated with significant morbidity, prolonged hospital stay, high mortality of 40% to
60%  and increased health care costs[45].
C. albicans was  the  predominant  species  to  cause  (40-60%)  invasive
candidiasis[11,46]. However, a shift towards non- Candida albicans (NCA) species with
C.tropicalis (25%), C.glabrata (8%),C.parapsilosis(7%),C.krusei(4%) are reported .
They are of special concern due to  high virulence nature and reduced susceptibility to
antifungal agents, so identification to species level and susceptibility testing are
recommended that all fungi obtained from sterile sites and urine of
immunocompromised patients [47] .
Candidemia rates increased rapidly since 1980s and Candida spp was  the
fourth-commonest cause of bloodstream infection (BSI) [48] . However in the late 1990s
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C. albicans incidence as BSI was decreased[49]  but the incidence of NCA BSI mostly
due to Candida glabrata  remained stable. Prior surgery, acute renal failure,
neutropenia, antibacterial agents, parenteral nutrition and central venous catheters were
associated with an increased risk of invasive candidiasis.[50]
Cryptococcosis[24]:
           Cryptococcosis is also known as torulosis or European Blastomycosis. The
prevalence of cryptococcosis varies from 3- 6% in Europe, 6-10% in  USA and 10-30%
in Central Africa. Cryptococcosis caused by the capsulated yeast Cryptococcus
neoformans, is principally a disease of the central nervous system, although the primary
site of infection is the lungs(30-40%). Almost all cases are caused by C. neoformans
var. neoformans.[51-53]
Cryptococcal meningitis occurs most frequently in patients with abnormal T
lymphocyte function. These include patients with AIDS, Hodgkin's disease, collagen
disease and neoplasms.
A mild, self-limiting pulmonary infection is believed to be the commonest form
of cryptococcosis which represents the primary infection. In a proportion of patients,
the disease will progress to a chronic meningitis or meningoencephalitis.
Cryptococcus neoformans var grubii causes manifestation in HIV positive
patients where as Cryptococcus neoformans var neoformans are more common among
patients on corticosteroids[42].AIDS patients with Cryptococcosis mostly develop
chronic meningeal form and the symptoms tend to be milder than in other patients.
Cryptococcosis in AIDS patients is considered incurable and needs lifelong therapy to
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suppress the infection. A positive serum Cryptococcal antigen is reliable for the
diagnosis of disseminated disease.[47,54].
Invasive Aspergillosis
Invasive Aspergillosis (IA) is the second most common cause for  invasive
mycosis[11,55] accounting  for  10  to  20%  of  all  cases[11]. Aspergillus spp. can lead to
invasive aspergillosis, tracheobronchitis, aspergilloma and chronic necrotizing
aspergillosis mainly in immmunocompromised hosts, including neutropenic
(particularly if >3 weeks) cancer patients, patients treated with immunosuppressive
therapies (corticosteroids, cytotoxic agents or monoclonal antibodies acting as anti-
immune mediators) [7] and  in  AIDS  patients.  IA  was  also  reported  in  <1%  of  renal
transplant recipients [56] .
The  most  frequent  site  of  IA is  the  lower  respiratory  tract  which  accounts  for
about 80 to 90%[11]. Other clinical manifestations include sinusitis, central nervous
system (CNS) infections and disseminated infection involving multiple sites [7, 57].
A.fumigatus is the predominant Aspergillus spp isolated from IA accounting for
more than 90%, followed by A. flavus, A. terreus and A. niger[11]. However, a shift  in
the epidemiology of Aspergillus infections by non-fumigatus Aspergillus species, such
as A. terreus which is resistant to amphotericin B are seen.
Accurate diagnosis of invasive infection, particularly aspergillosis, remains
problematic in patients with haematological malignancy, in whom signs and symptoms
are nonspecific and often develop late in the course of infection. Mortality from
aspergillosis is 70% if diagnosis is delayed. [10]
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EMERGING MOULDS:
Fusarium spp is a filamentous fungus widely distributed on plants, in soil and
in water[58-60]. Currently, there are over 50 known species of Fusarium, and only some
causing infections in humans[61].  Notably, Fusarium spp is an emerging cause of
opportunistic mycoses. Fusarium  enters the  host most commonly through the airways,
via inhalation of aerosolized conidia. Nosocomial infections have been reported and
may  be  caused  by  contamination  of  hospital  water  systems  or  hospital  plants.  Most
commonly, Fusarium spp  affects cancer patients, particularly those with acute
leukemia, but can affect other immunocompromised hosts[17,62,63].
Zygomycosis[24] is a disease caused by members of the Mucorales. The disease
classically involves the rhino-facial-cranial area, lungs, gastrointestinal tract, or less
commonly other organ systems. The disease is associated with the diabetic keto
acidosis,severely burned patients and other diseases such as leukemia and lymphoma,
immunosuppressive therapy and corticosteroids. The fungi show a predilection for
vessel (arterial) invasion resulting in embolization and necrosis of surrounding tissue.
Infections are typically acute and fulminant. Rhinocerebral disease in acidotic patients
usually results in death, often within a few days and the prognosis is grave[24].
Other moulds like Penicillium  spp ,Scedosporium spp, (hyalohyphomycoses) ,
and dematatious fungi(Phaeohyphomycosis)[46] are also capable of causing a wide
variety of IFI in immunocompromised host.[64].
RISK FACTORS FOR INVASIVE FUNGAL INFECTIONS[46]
? Acquired-  infection such as HIV, prior invasive  fungal infections and
certain cancers including leukemia, lymphoma, or multiple myeloma,
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Central Venous or urinary catheter, Prolonged stay in ICU, major surgery,
burns etc
? Chronic diseases -  such  as  end  stage  renal  disease  and  dialysis,  diabetes,
cirrhosis
? Medications - such as steroids, chemotherapy, radiation,
immunosuppressive post-transplant medications
FUNGAL PATHOGENICITY
The  mechanism  of  fungal  pathogenicity  depends  on  its  ability  to  adapt  to  the
tissue environment of the host and to withstand the lytic activity of the host’s
defenses[51].The ability of fungi to invade tissue to cause human disease are primarily
related to the immunological status of the host and environmental exposure. [35,51,65,66].
Most fungi are unable to grow at 37°C. Hence, thermo tolerance is essential to
survive  at  this  temperature  for  the  fungi  to  grow within  human body.  Most  fungi  are
saprophytic and their enzymatic pathways functions better at the redox potential of non-
living substrates than at the lowered oxidation-reduction state of living tissue.
However, many fungi prove to be able to surpass these two major physiologic
barriers[51] .
Host defenses are of non-specific and specific nature.
NON-SPECIFIC DEFENSE MECHANISM :
? Antifungal activity of natural excretions, such as saliva and sweat;
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? Protective effects of the endogenous normal micro biota of the skin and mucous
membranes
? Mechanical barrier of the skin and mucous membranes preventing entry of
fungi.
? Presence of highly efficient non-specific inflammatory system(neutrophils,
mono- nuclear phagocytes and other granulocytes) to combat fungal
proliferation
SPECIFIC DEFENCE MECHANISM: by acquired immunity defending from fungal
growth in tissue consist basically of
? Cell mediated immunity regulated by T-lymphocytes
? Humoral immunity regulated by B-lymphocytes
Predisposing factors associated to defects in the host defenses against fungi[35,51]:
1) Disturbance in the epithelial barrier by:
• Broad spectrum or multiple antibiotic therapy
• Indwelling catheters
• Peritoneal dialysis
• Burns, ulcers, trauma, surgeries etc
• Increased gastric pH, cytotoxins, radiotherapy
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2) Defects or dysfunction of mononuclear phagocytes, neutrophils and other cells
caused by:
• Chemotherapy, radiotherapy
• Aplastic anaemia
• Chronic granulomatous disease
• Diabetes mellitus
3) Defect or dysfunction of T-lymphocyte resulting in poor cell mediated immunity
caused by:
• AIDS
• Hodgkin’s disease and Non hodgkins disease
• Post transplant patients on immunosuppressants
• Chemotherapy and radiotherapy
• Leukemia and Carcinoma
• Corticosteroids
SPECIMEN COLLECTION AND PROCESSING:
The laboratory diagnosis starts with collection of appropriate specimen. The
anatomical site in which the organism is present must be carefully selected and the
specimen collected in such a manner that it will allow the fungus to remain viable in its
‘natural’ state with no contamination. The collection, transport and processing of
clinical specimens encompass one of the most important consideration in determining
the etiology of fungal disease. Under strict aseptic precautions samples are collected
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from the patients and transported immediately to the laboratory in appropriate settings
and sample processing done.
SPECIMENS:
The  following  fungal  species  were  most  commonly  recovered  from  the  clinical
specimens:[67]
Blood Pus and other exudates Respiratory secretions
• Candida spp
• Cryptococcus neoformans
• Histoplasma capsulatum
• filamentous fungi are
rarely isolated from blood
with exception of Fusarium
spp
• Cryptococcus neoformans
• Dimorphic fungi
• Fusarium spp
• Aspergillus spp
• Candida spp
• Cryptococcus neoformans
• Dimorphic fungi
• Mucor spp
•Scedosporium apiospermum
• Rhizopus spp
Miscellaneous body fluids
Cerebrospinal fluid Urine Vitreous Fluid Synovial Fluid
•Cryptococcus
neoformans
• Candida spp
• Coccidioides immitis
• Histoplasma
capsulatum
• Candida spp
• Cryptococcus
neoformans
• Candida albicans
(most common)
• Aspergillus spp
• Candida spp
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CLINICAL FEATURES:
Clinical symptoms of IFI are often non-specific, therefore a high index of
suspicion in high risk patients is necessary for timely diagnosis and prompt treatment.
Diagnosis of the IFI could be challenging, particularly in severely
immunocompromised patients as a result of blunted inflammatory response due to
profound neutropenia and altered T-cell function; hence, in such patients clinical and
radiologic findings may be very subtle.
The most common clinical signs are the symptoms of local or generalized
inflammatory response, primarily persistent fever despite the use of broad spectrum
antibiotics. Other symptoms significantly depend upon the involved anatomic site and
causative pathogen.
Diagnosis of systemic fungal infection based on clinical features
and/or laboratory parameters : [68]
Esophagitis
• Endoscopically visualized plaques in the esophagus are clinically suggestive of
fungal infection
• Positive fungal culture
• Pseudohyphae on Gram stain or on biopsy demonstrate invasive fungal
elements
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Pneumonia
FEATURES OF ASPERGILLUS, PSEUDALLESCHERIA, AND FUSARIUM
PNEUMONIA:
• Persistent or progressive pulmonary infiltrate refractory to antibacterial
therapy
• Clinical symptoms of pneumonia (fever, cough, haemoptysis, dyspnea,
pleuritic pain, rales, and bronchial or pleural rub)
 • Characteristic chest X-ray or CT findings:
? Subpleural radiologic densities, nodules, and wedge-shaped or cavitating
lesions
? ‘Air crescent’ or ‘halo sign’ on CT scan
?  Progression of lesions from infiltrates to cavity or crescent lesions
Urinary tract infection
• Signs and symptoms of bladder irritation (dysuria, hematuria, frequency,
urgency, and suprapubic tenderness)
• Clean catch midstream or catheterized urine sediment containing 104
cfu/ml of Candida spp.
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Fungemia
• At least one positive blood culture yielding fungus during a febrile
episode
• Persistent Candida antigenemia
Abscess from deep sites(Brain abscess):
• Radiographic evidence of inflammatory focus
• Positive fungal culture from biopsy or aspiration
Endophthalmitis
• Ophthalmoscopic examination suggestive of endophthalmitis
• Positive fungal culture from either the eye, blood, or other sites of
dissemination
INVESTIGATION
To improve outcomes of high risk patients it is critical to establish the diagnosis
of  IFI  early,  but  currently  there  is  no  single  diagnostic  method  that  has  a  sufficient
sensitivity and specificity to determine IFI. Therefore, timely diagnosis of IFI should be
made on the basis of a constellation of clinical signs, confirmatory imaging studies and
laboratory findings.
? Complete Blood count: Haemoglobulin %, ESR, Total count, Differential count,
Platelet count
? Blood sugar level
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? Liver function test
? Renal function test
? HIV testing and CD4 count
IMAGING STUDIES:
(i) PLAIN  RADIOGRAPHY:  Even  minor  abnormalities  on  chest  radiographs
(CXR) in high risk patients should prompt further investigation, which often
includes computed tomography (CT) of the chest.  CXR may be negative in up
to 10% cases of invasive pulmonary Aspergillosis.
(ii) COMPUTED  TOMOGRAPHY:  When  suspicion  for   invasive  pulmonary
Aspergillosis is high, it is very important to pursue CT imaging of chest[69].
CT findings that are more specific for IA are:
? “Halo sign” as a early finding when the central nodular area of
fungal invasion is surrounded by a ground-glass appearing
hemorrhage
? “Crescent sign" occur later as a result of necrosis and cavitation of
lung tissue
(iii) MAGNETIC RESONANCE IMAGING: MRI is recommended for infections
impending into orbit and intracranial compartment.
(iv) ENDOSCOPY: Upper gastrointestinal(UGI) endoscopy for invasive esophageal
candidiasis  and cystoscopy for bladder IFI.
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MICROBIOLOGICAL LABORATORY DIAGNOSIS:
DIRECT EXAMINATION: [42]
WET MOUNT: Yeast cells and hyphal elements of the organism can be readily
observed in routine 10% Potassium hydroxide preparations with or without fluorescent
compound such as calcoflour white are used. For CSF samples, India ink or 10%
Nigrosin negative stain preparation performed.
STAINING: Identifications are also aided by fungal stains such as Gomori
methenamine silver, Periodic Acid Schiff in tissue. Zygomycetes stain poorly by
Periodic Acid Schiff stain but stains better with H&E and  Gomori methenamine silver.
As most of the organisms are common lab contaminants, microscopic
demonstration of the presence of them in clinical material taken from lesion is
significant.
CULTURE:
Non  selective  types  of  culture  media  are  essential  for  primary  isolation  of  fungi
from clinical specimens. A combination of media is always better because it broadens
the chances of isolating etiological agent. Various t types of culture media available for
fungus isolation are[42]:
A. BASAL MEDIA:
1) SABOURAUD DEXTROSE AGAR:
SAB agar is the standard medium for recovery and maintenance of a
wide variety of fungi commonly isolated in the clinical laboratory
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because it provides basic nutrients that supports the growth of almost all
fungi.
B. NUTRITIONALLY DEFICIENT MEDIA:
1) CORN MEAL AGAR(CMA):
Mostly used for chlamydospore production in yeast isolates.
2) RICE STARCH AGAR:
Used for chlamydospore formation faster than CMA in yeast isolates
C. ENRICHED AND SELECTIVE MEDIA:
1) BRAIN HEART INFUSION AGAR:
BHI is an enriched medium that enhances the recovery of Cryptococcus
neoformans and fastidious pathogenic fungi from sterile specimens such
as CSF
2) BIPHASIC MEDIUM:
This medium is used to isolate fungi from blood cultures.
3) SHEEP BLOOD AGAR:
Used for isolation of Cryptococcus spp.
4) CZAPEK-DOX AGAR:
This medium is useful for isolation of Aspergillus and Penicillium spp.
5) MALT EXTRACT AGAR:
This medium is used for maintenance of fungi in mycology laboratory. It
is also an effective  alternate media for the isolation of zygomycetes.
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6) POTATO DEXTROSE AGAR:
This  medium  is  used  for  stimulation  of  sporulation  and  pigment
production.
ANTIGEN DETECTION
In immunocompromised patients with invasive disease who cannot mount good
immune response, antigen detection may be very useful. Several tests are available for
detection  of soluble antigen of Candida spp, Cryptococcus spp and Aspergillus spp in
serum, urine or other body fluids. Radio immune assay, Enzyme linked immunesorbant
assay, Latex agglutination and  Limulus lysate assay are most commonly used methods.
Commercially available kits are Latex agglutination for Cryptococcus spp, G or Glucan
test for Candida spp and Aspergillus spp and Galactomannan test for Aspergillus
spp.These tests helps in earliest diagnosis of Invasive infection[ 42].
MOLECULAR DIAGNOSIS:
(i) NUCLEIC ACID DETECTION TECHNIQUES: Though highly sensitive and
specific,  they are still  in experimental  stage.  Polymerase chain reaction (PCR),
Nested PCR, Real time PCR, Branched DNA Technology though helps in
detection and quantification of fungal DNA diagnosis in clinical specimens but
cannot differentiate whether the organism is pathogen or colonizer[70].
(ii) TYPING OR SEQUENSING SYSTEMS: It is done mainly for epidemiological
studies. Pulsed- Field Gel Electrophoresis, Restriction fragment length
polymorphism analysis, Random amplified polymorphic DNA analysis are
methods available[71].
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Overview of Fungal Diagnostic Techniques[46]
Method Pathogen(s)
Detected
Comments
Traditional Methods
Culture All Replication time for fungi is longer than
bacteria and takes a longer time to
complete; may be negative for certain
fungal pathogens; unable to differentiate
colonization from true pathogen;
requires invasive specimen
Histopathology All Cannot confirm identification because
many pathogens are morphologically
similar; requires invasive specimen
Radiology All Cannot identify specific pathogen and
difficult to distinguish from bacterial or
other causes; lack of response in
immunosuppressed patients results in
false-negative results
Rapid Diagnostic Tools
Galactomannan Aspergillus only False positive occurs with ?-lactam
antibiotics; low sensitivity in solid-organ
transplant recipients; controversy exits
regarding positive test cutoffa
Beta-glucan Candida spp. and
Aspergillus only
False positive occurs with dialysis
filters, albumin, immune globulin;
controversy exits regarding positive test
cutoffb
Fungal PCR All test is specific
to organism
Commercially not available
PNA FISH Candida albicans
and Candida
glabrata
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(i) aControversy exists regarding cutoff for a positive test should be greater than
0.5 or 1.
(ii) bControversy exists regarding cutoff for a positive test should be 60 pg/mL or
80 pg/mL.
ANTIFUNGAL SUSCEPTIBILITY TEST (AST)[42]:
The antifungal susceptibility testing is performed to provide information to
clinician to select an appropriate antifungal agent for a treating an infection and to
detect susceptibility pattern of the strain.There are various AST methods available, they
are:
I. CLSI METHODS: Clinical and laboratory standards institute at Wayne,
Pennsylvania deals with the susceptibility testing of various microorganisms
including fungi. The approved version of CLSI document M27-A2(1997) and
M38-A(1998) on standardized broth macro and micro broth dilution methods
for AST of yeasts and moulds respectively.
Critical facts affecting reproducibility of AST:
? Inoculum size and preparation
? Incubation time & temperature
? Media used
? End point criteria
? Stability of antifungal agent
? Growth rate of fungi
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BREAK POINT: Break point values detects the success or failure of an
antifungal agent.
MEASUREMENTS: the final reading is taken either by turbidity measurement
or colorimetric methods.
II. AGAR DILUTION METHOD: The aim of agar dilution method is to
determine the MIC, under defined test conditions which inhibits the visible
growth of the fungi being investigated. It involves incorporation of different
concentrations of the antimicrobial substance in yeast nitrogen base agar
medium followed by the application of a standardized number of cells on the
surface of the agar plate [72].
III. E TEST METHOD: It is based on a combination of dilution and diffusion test
principle and determines MIC. It is similar to disc diffusion method where, the
discs are replaced by a thin, inert and non-porous calibrated plastic strip (5 x 60
mm) impregnated with a stable concentration gradient(corresponding to 15- two
fold  dilution)  of  antifungal  compound.  The  results  of  E  test  and  broth  method
were promising for Candida spp but marked disparity was seen among
Cryptococcus spp.
IV. DISC DIFFUSION METHOD:  The CLSI document for this method is M44-
A. Disc containing antifungal agent placed on the surface of agar, diffuses into
the surrounding medium, inhibiting the growth of the fungi and measurements
of zone of inhibition are taken accordingly. Results are interpreted as:
? Susceptible: The zone diameter of test strain is more than 80% of control
strain
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? Intermediate or Susceptible dose dependent: The zone diameter of is less
than 80% of control strain
? Resistant : There is no zone of inhibition
V. FUNGITEST:  It is a microbroth dilution method based on CLSI M27-A2
standards. Test plate consists of disposable microplate with serial dilutions
dehydrated drugs & colorimetric indicator and they are reconstituted by adding
inoculums suspended  in  RPMI medium.  It  is  an  alternative  to  CLSI  reference
procedure[75].
VI. SPECTROPHOTOMETRIC METHOD: MIC is determined by reading broth
microdilution plates with yellow coloured tetrazolium salts as indicator, which
penetrates rapidly into the intact cells and converted to purple coloured
formazan in spectrophotometer.
VII. FLOW CYTOMETRY:  provides a rapid (4-6hrs) assay of antifungal activity
by detecting the accumulation of vital dye in drug damaged fungal cells.
VIII. OTHERS: BacT/Alert can be tried for AST.
  TREATMENT:
I. Surgical therapy:
Debridement of grossly infected and devitalized tissue is mandatory if lesion is
localized. They have been tried for deep abscesses and lung infections.
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II. Antifungal therapy:
There are four common antifungal strategies used in current clinical practice to
combat IFI. These include antifungal prophylaxis, empirical therapy, pre-
emptive (or diagnostics driven) therapy and treatment of proven and probable
IFI.
Clinically useful antifungals are:
? Polyenes: Amphotericin B, Amphotericin B lipid formulation
? Azoles: Fluconazole,Itraconazole,Voriconazole,Posaconazole
? Echinocandins: Caspofungin,Micafungin,Anidulafungin
? Miscellaneous: Flucytosine
AMPHOTERICIN B:[7,11,76]
Mechanism of action: it binds to ergosterol in fungal cytoplasmic membrane,
increasing permeability and causing leakage of intracellular components.
Spectrum of activity: good activity against most Candida spp, Aspergillus spp,
Cryptococcus spp and dimorphic moulds.
LIPID FORMULATIONS OF AMPHOTERICIN B:
? Amphotericin B colloidal dispersion(ABCD)
? Amphotericin B lipid complex(ABLC)
? Liposomal Amphotericin B
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Dosage:
Dose/Route Amphotericin B ABCD ABLC Liposomal Amphotericin B
mg/kg/iv 0.5-1 1.5 5 3
AZOLES[7,11,19-21,77-79]:
Mechanism of action: inhibits cytochrome P-450 dependent lanosterol 14-
demethylase, an enzyme needed for synthesis of ergosterol, which form the main
component of  fungal cell membrane. This results in accumulation of methylated
sterols, depletion of ergosterol and inhibition of cell growth.
Spectrum of activity:
Pattern of susceptibility of Yeast and Yeast like isolates for various azoles:
Organisms Fluconazole Itraconazole Voriconazole Posaconazole
Cryptococcus
neoformans
S - S R
Candida albicans S S S S
Candida tropicalis S S S S
Candida parapsilosis S S S S
Candida glabrata SDD to R SDD to R S to I S
Candida krusei R SDD to R S S
Candida lusitaniae S S S S
S: Susceptible; SDD: Susceptible dose dependent; I: Intermediate; R: Resistant;
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Pattern of susceptibility of filamentous fungi isolates for various azoles:
Organisms Itraconazole Voriconazole Posaconazole
A.fumigatus + ++ ++
A.flavus ++ ++ ++
A.terreus +/- + ++
A.nidulans ++ ++ +
Penicillium spp ++ ++ +
Fusarium spp - - -/+
Rhizopus spp -/+ - ++
Mucor spp -/+ - +
Dematiaceous fungi +/++ +/++ +/++
Dimorphic fungi ++ ++ -
Dosage  Fluconazole Itraconazole Voriconazole Posaconazole
200mg b.i.d 200mg b.i.d 200mg q12h
Or
6mg/kg q12h IV
100mg b.i.d
ECHINOCANDINS[7,11,89]:
Mechanism of action: Non competitive inhibition of enzyme glucan synthase
which produces (1,3)? d glucan. Destruction of cell wall leads to osmotic instability
and lysis of fungal cell
Types:
? Caspofungin: Candidiasis  in febrile neutropenic patients
? Micafungin: Invasive/ Esophageal Candidiasis
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? Anidulafungin: Candidiasis in non neutropenic patients
Spectrum of activity of Caspofungin:
Potent fungicidal activity was seen against Candida spp and variable activity
against Aspergillus spp and Dimorphic fungi.
Dosage: 70mg iv loading dose followed by a daily 50mg iv dose
FLUCYTOSINE: (5-FLUOROCYTOSINE) – 5-FC pyrimidine anologue[ 91]
Mechanism of action: By fungal cytosine deaminase enzyme ,5-FC is converted
to an antimetabolite 5- Flurouracil which inhibits thymidylate synthetase needed for
synthesis of DNA. So it acts by inhibiting DNA synthesis.
Spectrum of activity: has only narrow spectrum activity (action against Candida spp,
Cryptococcus neoformans and few pheoid fungi.
Dosage:
? oral tablets - 25 mg/kg at 6 h intervals
? parenteral administration- 10 mg/ml in saline solution.
MATERIALS
AND
METHODS
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MATERIALS AND METHODS
STUDY PLACE:
This cross sectional study was conducted in the Institute of Microbiology in
association with the Institute of Dialectology, Department of Nephrology, Department
of Haematology and Department of Oncology, Madras Medical College and Rajiv
Gandhi Government General Hospital, Chennai-3.
STUDY PERIOD:
The study was undertaken for a period of one year from September 2011 to
August 2012.
ETHICAL CONSIDERATIONS:
Approval for the study was obtained from   the Institutional Ethical Committee,
Madras Medical College    and Rajiv Gandhi Government General Hospital, Chennai-3
before commencing it.  Informed   consent  was  obtained  from  the  study  population.
All patients satisfying the inclusion criteria were documented. Patients were
interviewed by structured questionnaire.
STUDY POPULATION:
Inclusion criteria:
All  adults  more  than  18  years  of  age  with  following  clinical  conditions  were
included:
? Acquired Immunodeficiency syndrome patients.
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? Renal transplant patients on Immunosuppressive therapy for >30days
? Diabetic mellitus  patients.
? Carcinoma, Leukemia and Lymphoma patients on chemotherapy for >30
days
Exclusion criteria:
? Immunocompromised conditions due to various other reasons.
? Chronic diseases such as cirrhosis, tuberculosis, end stage renal disease
? Certain conditions like Chronic granulomatous disease, Collagen
vascular disease patients on steroid therapy.
? Burns patients & patients on dialysis
DATA COLLECTION:
Data collection included name, age, sex, address, IP number, date of admission,
diagnosis at admission, physical examination findings and demographic profile which
includes H/O Diabetes mellitus, Chronic kidney disease, neoplasm, immunosuppressive
therapy, previous IFI.
CASE DEFINITIONS:[41]
Invasive fungal infections are defined in terms of “PROVEN”, “PROBABLE”,
“POSSIBLE”,
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PROVEN IFI:
Moulds
? Histo/cytochemistry and / or KOH showing hyphae from a needle aspiration or
biopsy
? Positive culture obtained by sterile procedure from a normally sterile site  and
clinically and radiologically abnormal site consistent with infection.
? Positive blood culture of fungi excluding Aspergillus spp and Penicillium spp
other than P.marneffei, accompanied with clinical manifestations.
Yeasts
? Histo/cytochemistry showing yeast cells and/or pseudohyphae from a biopsy or
needle aspiration excluding mucous membranes
? Positive culture obtained by a sterile procedure from a normally sterile and
clinically or radiologically abnormal site consistent with infection excluding
urine, sinuses, and mucous membranes
? India ink or antigen positivity for Cryptococcus spp in CSF
? Positive blood culture of Candida spp.
PROBABLE IFI:
? Atleast one criteria from host factor, one microbiological criteria and one major
(or two minor) clinical criteria from abnormal site consistent with infection.
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POSSIBLE IFI:
? Atleast one criteria from host factor and  one microbiological criteria or one
major (or two minor) clinical criteria from abnormal site consistent with
infection.
SAMPLE COLLECTION:
         Sample collection was done according to American Thoracic Society
Recommendations for fungal culture[82]
SPECIMEN RECOMMENDED PROCEDURE
Sputum First early morning sample collected before breakfast after vigorous
rinsing of mouth with water. Sputum was coughed out following a
deep breath, collected into a sterile, screw capped container.
If an adequate specimen cannot be obtained, then production was
induced  with heated aerosol saline suspension
Bronchoscopy Bronchial brushing, biopsy or broncho alveolar lavage fluid
collected and transported in sterile sealed container
Cerebrospinal
fluid(CSF)
As much CSF as possible collected aseptically transported in sterile
sealed container and processed without delay. If delayed sample left
at room temperature
Urine First early morning clean catch mid stream urine specimen
collected aseptically in sterile, screw capped container and
processed immediately. If delay of >2hrs anticipated, sample should
be refrigerated at 4oC
Exudates After using disinfectant, exudates from deep abscess site aspirated
using sterile needle and syringe.
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Tissue biopsy Biopsy from lesion site taken and transported in a sterile gauze
moistened with physiologic, non bacteriostatic, sterile saline
solution in a screw capped container
Blood After disinfecting the venipuncture site with 70% alcohol, 2 sets of
blood  sample  collected   from  right  and  left  arm(>20ml/set)  at  the
time of febrile episode in a sterile culture broth
GUIDELINES FOR SPECIMEN COLLECTION:[82]
? Specimen must be collected from an active lesion containing viable organisms
? Specimen must be collected under sterile aseptic precautions
? Sufficient specimen must be collected
? Specimen must be collected before instituting therapy
? Sterile collection devices and containers must be used
? Specimen must be labeled appropriately
CRITERIA FOR REJECTION: [82]
? Unlabelled samples
? Discrepancy between  the information on the request form and the container
label
? Specimen transported at improper temperature
? Specimen transport time if delayed
? Samples received in unsterile container
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? Samples collected in  insufficient volume
? Samples that have leaked or show signs of drying
? Samples received in formalin
PROCESSING OF SPECIMENS:[82]
All specimen are microscopically examined and cultured as soon as possible.When the
specimen reach the laboratory, they are appropriately processed to ensure viability of
the etiological agent and to minimize the chance of contamination.
SPECIMEN PROCESSING OF SPECIMEN
Respiratory
specimen
Most purulent or blood flecked parts of sample are selected to culture.
Highly viscid sample was homogenized by adding a pinch of
crystalline N-acetyl-L-Cystine. Since respiratory secretions were
contaminated with bacteria, media containing antibiotics was used for
primary isolation
Cerebrospinal
fluid(CSF)
CSF samples centrifuged at  1500-2000g for 20min and inoculated on
non inhibitory culture media.
Urine About 10ml of urine sample centrifuged, 0.5ml of sediment inoculated
on both inhibitory and non inhibitory agar medium.
Tissue Tissue was minced into 1mm cubes with sterile scissors or a sharp
scalpel blade and the tiny fragments were placed directly on agar&
submerging them slightly beneath
5-10 ml of tissue homogenate, bone marrow or body fluids were
sedimented and placed on non selective culture media since the
samples were sterile
Blood 5-10 ml of blood sample inoculated in biphasic media containing
brain heart infusion broth and agar.
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DIRECT EXAMINATION:[82,83]
POTASSIUM HYDROXIDE (KOH) MOUNT PREPARATION:
On a clean, grease free glass slide one large drop of 10% KOH was placed and a
small quantity of specimen was mixed with it. A sterile coverslip was placed over the
drop. The slide kept in a moist  chamber at  room temperature for 10 minutes to allow
the debris to clear. Observed under low and high power of the light microscope for the
presence of yeasts or hyphal forms.
CALCOFLUOR WHITE MOUNT:
Specimens were mixed with the water soluble, colourless dye Calcofluor white,
a  fluorescent  whitener   on  the  slide,  which  as  an  affinity  for  chitin  and  cellulose  of
fungal cell wall and favours demonstration of fungal elements more easier when
viewed under fluorescent microscope.
INDIA INK OR 10% NIGROSIN MOUNT: [NEGATIVE STAINING]
When Cryptococcus neoformans suspected, India ink mount was prepared with
a drop of centrifuged sediment and dye on the center of clean grease free slide and
mixed well with a loop and a sterile coverslip placed vertically such that one edge just
touches the fluid on the slide. keeping the edge in contact with the fluid surface,
coverslip dropped gently o the fluid so that no air bubble is trapped inside. Mount
examined microscopically for the presence of encapsulated, budding yeast cell.
SPECIAL STAINING TECHNIQUE:
Histologic evaluation of tissues is a quick and easy way to identify fungal
organisms, and a strong adjunct to microbiologic culture for diagnosis of fungal
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infections. So Simultaneously all the specimens were also processed in Institute of
Pathology, Madras  Medical College and Rajiv Gandhi Government General Hospital,
Chennai. Haematoxylin and Eosin stain was done routinely. Special stains like Giemsa,
Gomori Methenamine silver were also performed when fungal forms suspected in
H&E.
ANTIGEN DETECTION BY LATEX AGGLUTINATION TEST (LAT) - The
supernatant from the centrifuged CSF sample was inactivated by placing in a boiling
water bath for 5 minutes to reduce non-specific interference in the test. The kit used
was Cryptococcal Antigen Latex Agglutination System (CALAS), [Meridian
Biosciences]. The following procedure was followed-
1. One drop of positive control was added to each of the two designated rings.
2.  25 µl of the antibody control and negative control were added to the
appropriate rings.
3. 25 µl of CSF sample was added to each of the two designated rings.
4. One drop of detection latex was added to each of the designated rings.
5. Similarly, one drop of control latex was added to each of the designated rings.
6. The contents of the rings were mixed using separate applicator sticks.
7. The card was rotated at 125 rpm for 5 minutes on a rotator and the reaction was
graded as follows:
a) Negative: homogenous suspension of particles with no visible clumping
b) 1+ : fine granulation against a milky background
c) 2+: small but definite clumps against a slightly cloudy background
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d) 3+: large and small clumps against a clear background
e) 4+ large clumps against a very clear background
A reaction of 2+ or more with the detection latex was taken as positive for the
presence of cryptococcal polysaccharide antigen in the CSF
CULTURE:[82]
A minimum amount of specimen was inoculated onto 2 slants of Sabouraud
Dextrose Agar of pH 5.6 with antibiotics gentamycin added at a concentration of
20mg/liter[37] . Inoculated tubes were incubated at 25 and 37oC.  Tubes were daily
examined for a week for growth. Cultures were incubated for a period of 4-6 weeks
before discarding the tubes as sterile and negative. Brain heart infusion biphasic culture
bottles with antibiotics was used for the recovery of fungi from blood samples.
INTERPRETATION OF FUNGAL CULTURE:
The following features helps in distinguishing contaminants from pathogen[42]:
? Isolation of same strain in all culture tubes
? Repeated isolation of same strain in multiple specimens
? Immune status of the patient
? Direct microscopic detection of fungal forms
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IDENTIFICATION OF FUNGAL ISOLATES:[42]
All isolates were systematically identified by standard techniques
YEAST:
The biochemical rather than morphological criteria used for identification of
Yeasts. Biochemical reaction includes ability to assimilate and ferment sugars, Germ
tube production, Chlamydospores production on corn meal agar. Special media  like
CHROMagar or Caffeic acid agar.
CAFFEIC ACID AGAR:
 Pathogenic Cryptococcus neoformans when grown on the medium containing
Caffeic acid agar produces dark or black colonies on incubating at 35oC for 3-5 days,
because of phenol oxidase produced by organism oxidizes caffeic acid into melanin.
CHROM AGAR SYSTEM:
This is a novel differential and selective culture medium for isolation and
presumptive identification of different species of Candida. The species of Candida can
be identified by different coloured colonies produced due to the reaction between
specific enzymes of the different species and the chromogenic substrates in the system,
which are as follows:
? C.albicans-light green
? C.dubliniensis- dark green
? C.glabrata-pink to purple
? C.krusei-pink
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? C.parapsilosis-cream to pale pink
? C.tropicalis-blue with pink halo
GERM TUBE PRODUCTION(REYNOLDS-BRAUDE PHENOMENON)
The culture of Candida species was  treated with 0.5ml of serum  and  incubated
at 37oC for 2 hours. A drop of suspension was  kept on the slide and examined under
the microscope. The germ  tubes were seen as  long  tube  like projections extending
from the yeasts cells.
SUGAR ASSIMILATION:
 6.7% Yeast nitrogen base with 2% agar concentration(twin pack
Himedia,Mumbai) plates were prepared and carbohydrate containing filter paper discs
with 4% concentration were placed and incubated at 35oC overnight. Carbohydrate
utilization is determined by growth around disc[42,123].
Fungus Maltose Sucrose Galactose Cellobiose Inositol Raffinose Dulcitol Starch
C.albicans + + + 0 0 0 0 +
C.tropicalis + + + + 0 0 0 +
C.glabrata 0 0 0 0 0 0 + 0
C.parapsilosis + + + 0 0 0 0 0
C.neoformans + + + + + + 0 +
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SUGAR FERMENTATION:
1% peptone water supplemented with different carbohydrates of 2%
concentration, a colour indicator to assess the pH changes to measure acid production
and a tool to assess gas production(by using an inverted Durhams tube). The tubes were
incubated at  300C  for  24-48 hours.  The colour change in the tube containing the
particular sugar indicates the yeast’s ability to ferment carbohydrate[42,123].
Fungus Glucose Maltose Sucrose Lactose Galactose Trehalose
C.albicans + + 0 0 + +
C.tropicalis + + + 0 + +
C.glabrata + 0 0 0 0 0
C.parapsilosis + 0 0 0 0 0
UREASE TEST:
Detection of urease activity of Cryptococcus was performed using Christensen’s
urease medium. Using a loop, a small amount of pure growth from a 48-72hr old
culture was inoculated on urease slants and the tubes were incubated at 30°C. If urease
is present in the isolate, urea is split to ammonia which raises the pH turning the slant to
deep pink colour due to the presence of phenol red indicator. The urease test was
declared negative only after 4 days. ATCC C.neoformans 32045 and ATCC C.albicans
90028 were used as positive and negative controls respectively.
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YEAST IDENTIFICATION SCHEME[83]:
This includes,
? Culture characteristics- colony colour, shape and texture
? Asexual structure-
? Shape and size of cells
? Type of budding- unipolar, bipolar, multipolar, fission
? Presence or absence of arthroconida, blastoconidia, germ tubes,
hyphae, pseudohyphae,
? Sexual structure- arrangement , cell wall, ornamentation, number, shape and
size of ascospores or basidiospores
? Physiological studies-
? Germ tube test
? Sugar fermentation
? Sugar assimilation
? Urea hydrolysis
FILAMENTOUS FUNGI:
MICROSCOPY: Various mounting methods performed includes:
a. Tease mount
b. Scotch tape
c. Slide culture technique
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Tease mount technique:
On a clean grease free microscopic slide a drop of lactophenol cotton
blue(LPCB)  was placed. A small portion of growth was removed midway between the
colony center and edge, placed on the drop of LPCB on slide. The growth was teased
using a pair of dissecting needles so as to have a thin spread out. Coverslip placed
gently at the edge of the drop of mounting fluid to  avoid trapping of air bubbles[42,83] &
mount was examined under microscope.
Scotch tape technique:
A drop of mounting fluid placed on the slide. 2cm long tape was taken with one
end touched to a forceps and other end to the colony. The tape with the surface
containing fungus was laid into the mounting fluid on slide. The tape was detached
from the forceps and mount was examined under microscope.
Slide culture technique[83]:
Setup:   In  a  100mm  glass  petridish,  a  filter  paper,  V-  shaped  glass  rod,  a
microscopic slide and a coverslip placed and the whole setup was autoclaved at 121oC
for 15 minutes.
Procedure:  1cm square agar block was cut aseptically from potato dextrose agar
and transferred to the slide in the setup.  A very small amount of the colony was
transferred to four sides of the agar block and coverslip was placed on the inoculated
agar block. 1-1.5 ml of sterile water  was added to filter paper to prevent drying of agar
block. 5% glycerin  was added to sterile water to prevent  condensation of moisture on
the slide. Slide culture was incubated in the dark at room temperature till good
sporulation occurs.
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Taking – down the slide culture:   A small drop of mounting fluid (LPCB) was
placed on a microscopic slide. With forceps, the coverslip was carefully removed, a
drop of 95% alcohol was added to coverslip to wet the colony and to prevent trapping
of air bubble and placed carefully on the mounting fluid and was examined under
microscope.
MOULD IDENTIFICATION SCHEME[83]:
This includes,
? Growth rate
? Colony characteristics – texture, colony(obverse, reverse), pigmentation
? Microscopy
(i) Fruiting structures: Synnemata, Pycnidia, Ascocarps
(ii) Hyphae : Colour, Size, Septation, Special structures
(iii) Conidiogenesis : Conidiogenous cell, Proliferation of conidiophores
ANTIFUNGAL SUSCEPTIBILITY TESTING[42,82-84,124]
Antifungal susceptibility testing of yeast and filamentous fungi was performed
as per CLSI guidelines. It was done by Kirby-Bauer disc diffusion method, Epsilometer
test, Broth  dilution method and agar dilution method.
MIC – MICROBROTH DILUTION METHOD
Amphotericin B powders were obtained from Himedia, Mumbai.
Itraconazole,Voriconazole and Fluconazole powders were obtained from Pharma
Fabricon, Madurai. Their potency were 750µg/mg each.
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STOCK SOLUTION:
For Water soluble drugs like Fluconazole sterile water was used  as solvent,
whereas for water insoluble drugs like Amphotericin B, Itraconazole and
Voriconazole,Dimethyl sulfoxide(DMSO) was used. Stock solution of 5200µg/ml for
Fluconazole and 1600µg/ml for other drugs was prepared. A series of dilutions at 100
times  the  final  concentration  was  prepared  from  stock  solution  in  RPMI  for
Fluconazole and with DMSO for others. Each intermediate solution was then further
diluted to final strength in RPMI test medium.
Weight (mg)  =   Volume(ml) x desired concentration(µg/ml)
                                       Assay potency(µg/ml)
Volume (ml) =   weight(mg)  x  Assay potency(µg/ml)
                                       concentration(µg/ml)
TEST MEDIUM USED: RPMI 1640(with glutamine, without bicarbonate, Phenol red
as pH indicator, Himedia ,Mumbai) with MOPS 0.165M
INOCULUM PREPARATION:
YEAST  (CLSI  M27-A2  protocol):  All  Yeast  fungi  were  subcultured  on
Sabouraud dextrose agar, incubated at 35oC for 24hours for Candida sp and 48hours for
C.neoformans. Colonies were suspended in sterile saline adjusted to 0.5McFarland. The
resulting yeast stock suspension of 1x106 to 5x106 cells/ml converted to working
suspension by diluting 1:100 dilution followed by 1:20 dilution with RPMI 1640 broth
medium, which results in5x102 to 2.5x103 cells per ml.
INCUBATION: All plates were incubated at 35oC and examined after 46-50
hours for Candida sp and upto 72 hours for C.neoformans.
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FILAMENTOUS FUNGI (CLSI M38-A protocol): All  organisms  were
subcultured onto Potato dextrose agar, incubated at 35oC for 7 days. The culture was
covered with 1ml sterile 0.85% saline and a suspension prepared by gently probing the
colonies. 1 drop of Tween 20 was added to help in dispersion of conidia. The resulting
mixture of conidia and hyphal elements was withdrawn and transferred to a sterile tube
and allowed to settle.  The uniform suspension was transferred to a screw capped tube
and  vortexed.  The  density  of  conidia  suspension  were  read  and  adjusted  to  a  optical
density of 0.09-0.11 for Aspergillus spp and 0.15 – 0.17 for Rhizopus spp by
Spectrophotometry. These will be diluted 1:50 in test medium, gives a density of
approximately 0.4x104 to 5x104 CFU/ml when mixed with antifungal agent.
             INCUBATION: All plates were incubated at 35oC and examined after 21-26
hours for Rhizopus and  after  46-50  hours  of  incubation  of Aspergillus spp and other
filamentous fungi.
INTERPRETATION:
Minimum inhibitory concentration is the lowest concentration of an antifungal
that substantially inhibits growth of the microorganism as detected visually. Each
microdilution well was then given a numerical score;
Score 4- No reduction of growth
Score 3- Slight reduction in growth(75% of growth control)
Score 2-Prominent reduction in growth(50% of growth control)
Score 1- slightly hazy
Score 0 -Optically clear or absence of growth
MIC for Amphotericin B – Score 0 and MIC for Azoles – score 2
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One growth well and one antifungal control well were also put in parallel.
ATCC A.flavus 204304, and ATCC C.krusei 6258 & ATCC C.parapsilosis 90018 were
used as quality control strain for filamentous fungi and yeast respectively. The
recommended MIC limits of ATCC A.flavus  were of 0.5 - 4µg/ml for Amphotericin B,
0.2 – 0.5µg/ml for Itraconazole, 0.5-4 µg/ml  for Voriconazole. The recommended MIC
ranges of ATCC C.krusei 6258  were 1-4µg/ml  for Amphotericin B, 16-128 µg/ml for
Fluconazole,0.25 – 1µg/ml for itraconazole and 0.25 – 1µg/ml voriconazole. The
recommended MIC ranges of ATCC C.parapsilosis 90018 were 0.5-2µg/ml  for
Amphotericin B and 0.25-1µg/ml for Fluconazole.
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PROCEDURE:
Procedure for  Water soluble Antifungal Agents  Used in microbroth Dilution
Susceptibility Tests
Drug –
Starting
Concentration
(µg/ml)
Stock
5120
2
4
160
8 16
32
20
64 128
256
2.5
511 Remarks
Tube # TUBE1
2X 4X 8X 2X 4X 8X 2X 4X 8X
TUBE
2
TUBE
3
TUBE
4
TUBE
5
TUBE
6
TUBE
7
TUBE
8
TUBE
9
TUBE
10
Source
Add DRUG
Amount (ml)
+
From
Stock
1.0
From
Tube
1
1.0
+
From
Tube
1
1.0
+
From
Tube
3
0.5
+
From
Tube
3
0.5
+
From
Tube
3
0.5
+
From
Tube
6
1.0
+
From
Tube
6
0.5
+
From
Tube
6
0.5
+
From
Tube
9
1.0
+
Step 1
Row 1
Add Solvent
RPMI (ml) 7.0 1.0 3.0 1.0 1.5 3.5 1.0 1.5 3.5 1.0
Intermediate
Drug
Concentration
(µg/ml)
640 320 160 80 40 20 10 5 2.5 1.25
Add Drug
from Tube
Row 1
Above (ml)
+
1.0
+
1.0
+
1.0
+
1.0
+
1.0
+
1.0
+
1.0
+
1.0
+
1.0
+
1.0
+
Step 2
Row 2
5X
(1:4)
RPMI 1640
(ml) 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0
Final
Concentration
at 1:5 (µg/ml)
128 64 32 16 8 4 2 1 0.5 0.25 (2X)
From  Row  2
add Drug to
Micro liter
plate (ml)
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Step 3(1:1)
Add
Inoculum to
Plate (ml)
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Step 4
(T.Vol
0.2ml)
FINAL
DRUG
CONC in
Well  at  1:
100 (µg/ml)
64 32 16 8 4 2 1 0.5 0.25 0.125
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Procedure for Water Insoluble Antifungal Agents  Used in microbroth Dilution
Susceptibility Tests
Drug –
Starting
Concentration
(µg/ml)
1,600 2 4
8
200
16 32
64
25
128 258 511 Remarks
Tube #
TUBE
1
(Stock)
(100
X)
2X 4X 8X 2X 4X 8X 2X 4X 8X
TUBE
2
TUBE
3
TUBE
4
TUBE
5
TUBE
6
TUBE
7
TUBE
8
TUBE
9
TUBE
10
Source
Add DRUG
Amount (ml)
+
From
Tube 1
-
From
Tube
1
0.5
+
From
Tube
1
0.5
+
From
Tube
1
0.5
+
From
Tube
4
0.5
+
From
Tube
4
0.5
+
From
Tube
4
0.5
+
From
Tube
7
0.5
+
From
Tube
7
0.5
+
From
Tube
7
0.5
+
Step 1
Row 1
Add Solvent
DMSO (ml) - 0.5 1.5 3.5 0.5 1.5 3.5 0.5 1.5 3.5
Intermediate
Drug
Concentration
(µg/ml)
1,600 800 400 200 100 50 25 12.5 6.25 3.13
Add Drug
from Tube
Row 1
Above (ml)
+
0.1
+
0.1
+
0.1
+
0.1
+
0.1
+
0.1
+
0.1
+
0.1
+
0.1
+
0.1
+
Step 2
Row 2
(1:50)
RPMI 1640
(ml) 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9
Final
Concentration
at 1:50
(µg/ml)
32 16 8.0 4.0 2.0 1.0 0.5 0.25 0.125 0.0625 (2X)
From  Row  2
add Drug to
Micro liter
plate (ml)
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Step 3(1:1)
Add
Inoculum to
Plate (ml)
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Step 4
(T.Vol
0.2ml)
FINAL
DRUG
CONC in
Well  at  1:
100 (µg/ml)
16 8 4 2 1 0.5 0.25 0.125 0.0625 0.0313
DMSO = Dimethy Sulfoxide
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CLINICAL SIGNIFICANCE:
YEAST:
AMPHOTERICIN B: MIC above 1µg/ml have been associated with treatment
failure and MIC below 1µg/ml with clinical cure
AZOLES: Organism was read as susceptible to fluconazole  when MIC<8
µg/ml, Susceptible Dose Dependent 16-32µg/ml and Resistant if >64µg/ml. For other
azoles most isolates of  MIC<1µg/ml are associated with clinical cure to the drug. Data
are not yet available to indicate a correlation between MIC and outcome of treatment
with the new azoles.
FILAMENTOUS FUNGI
AMPHOTERICIN B: MIC above 2µg/ml have been associated with treatment
failure and MIC below 2µg/ml with clinical cure
AZOLES: Preliminary data indicate high Itraconazole MIC’s (MIC>8µg/ml)
are associated with clinical resistance to the drug. Data are not yet available to indicate
a correlation between MIC and outcome of treatment with the new azoles.
DISC DIFFUSION:
Inoculum transmittance was adjusted according to CLSI M38-A protocol as
described above for microbroth dilution method. Suspension was applied to the surface
of Mueller Hinton agar with 2% glucose for disc diffusion[85] using swab
applicator(CLSI M44-A) .The inoculated plates were dried for 15 minutes.
Amphotericin B 10µg, Fluconazole 25µg and Itraconazole 10µg discs were used
(Himedia, Mumbai) [86]. Zone diameter were measured in disc diffusion assay to nearest
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whole  millimeter  at  the  point  where  there  was  a  prominent  reduction  of  growth  after
16-24 hours for Zygomycetes and after 48 and 72 hours for the other species[125].
The organism were interpreted as Susceptible, Susceptible Dose Dependent,
Resistant based on the following zone diameter:,[85]:
Drugs Susceptible
Susceptible Dose
Dependent
Resistant
Amphotericin B >15mm 13 – 14mm <12mm
Fluconazole <14mm 15-18mm >19mm
Itraconazole >17mm 14 – 16mm <13mm
EPSILOMETER TEST( E-TEST):
Inoculum suspension  for  E  test  was  prepared  similar  to  disc  diffusion  method
and plated on  RPMI agar [85] using swab applicator. Estrip of Amphotericin B,
Itraconazole and Fluconazole (Himedia, Mumbai ) was applied onto RPMI agar surface
[87]. E test was read after 24 hours or when there was sufficient growth to take a
reading[87-90]
AGAR DILUTION:
 Stock solution and drug dilutions were prepared according to the CLSI M38A
guidelines. For performing this technique, 1ml of Yeast nitrogen base was thoroughly
mixed with 18ml of 2% molten agar(Himedia,Mumbai) and 1ml of corresponding drug
dilution(0.0313 - 16µg/ml) and poured in sterile petri plates. Plates were dried prior to
use. The inoculum was adjusted   to 1.0x106 cells per ml establishing 90% transmission
at 530nm [91]. 10µl(0.01ml) amount was delivered on agar surface. A control plate
without antifungal drug was put. Inoculated plates were incubated at 30oC for 48 hours.
The MIC was defined as the lowest concentration which caused greater than 80%
inhibition of growth compared with growth on control plate.
RESULTS
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RESULTS
A total of 200  patients satisfying inclusion criteria, admitted with signs and
symptoms of  Invasive Fungal Infections  [IFI]  were  included in the study.  Out of 200
patients, 79 patients showed Fungal growth.
Table 1: Age and Sex distribution among study population (n=200)
Age
(years)
Risk Factors
Total
n (%)
Renal
Transplant
(RT)
Diabetes
Mellitus
(DM)
RT &
DM
Chemo
Therapy
(CT)
CT &
DM HIV
M F M F M F M F M F M F
18-20 3 2 2 1 - - 5 - - - 1 2 16 (8%)
21-30 18 11 4 3 1 - 3 2 - - 1 1 44(22%)
31-40 14 2 11 7 - - 6 2 - - 7 3 52(26%)
41-50 7 1 12 8 3 - 9 - 1 - 3 - 44(22%)
51-60 1 - 11 2 1 - 6 2 - 1 2 2 28(14%)
61-70 - - 4 2 - - 7 - - - 1 - 14(7%)
71-80 - - - - 1 - 1 - - - - - 2(1%)
Total n
(%) 43(22) 16(8) 44(22) 23(12) 6(3) - 37(19) 6(3) 1(1) 1(1) 15(8) 8(4) 200(100%)
The above table shows, the study consists of predominantly males (73%) when
compared  to  females  (27%).Out of 200 patients majority of them (26%) in the study
belong to the  age group of 31- 40 years, followed by equal number of distribution
among 21-30 and 41-50 years age group (22%).
CHART 1(A): SEX DISTRIBUTION AMONG STUDY POPULATION
CHART  1(B): AGE DISTRIBUTION AMONG STUDY POPULATION
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Table 2: Period of Immunosuppression favouring fungal infection (n=200)
Period of
Immunosuppression
Criteria
Renal
Transplant
Diabetes
Mellitus
(DM)
Renal
Transplant
& DM
Chemo
Therapy
(CT)
CT
&
DM
HIV Total
< 1 year 27 - 1 - - - 28(14%)
1 – 10 years 31 61 5 34 2 21 154(77%)
>10 years 1 6 - 9 - 2 18(9%)
Total 59(29.5%) 67(33.5%) 6(3%) 43(21.5%) 2(1%) 23
(11.5%)
200
In this study, Immunosuppressive period of 1 – 10 years showed increased incidence of
IFI among 154(77%) patients.
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Table 3: Distribution of samples collected from study population with various risk
factors (n=200)
Specimen
Risk factors Total
n(%)
Renal
Transplant
Diabetes
Mellitus
(DM)
Renal
Transplant
& DM
Chemo
Therapy
(CT)
CT
&
DM
HIV
Urine 23 35 1 - - - 59(29.5%)
Sputum 1 3 - 21 - - 25(12.5%)
Br. Wash 1 15 - 8 1 - 25(12.5%)
Drain /
Catheter 20 - 1 - - -
23(11.5%)
CSF 1 - - - - 18 19(9.5%)
Pus 4 3 1 1 - 1 10(5%)
Pleural fl - 2 - 6 - - 8(4%)
Blood 2 2 2 1 - - 7(3.5%)
Gastric
lavage 2 - - 2 - 2
6(3%)
BAL 1 3 - 1 - - 5(2.5%)
Ascitic fl. 1 - - 3 1 - 5(2.5%)
FNAC
aspirate - 4 1 - - -
5(2.5%)
Palatal
Scraping - - - - - 2
2(1%)
IV
Catheter
tip
1 - - - - -
1(0.5%)
Total 59 67 6 43 2 23 200
Among immunosuppressive patients in the study, the majority of samples were Urine
(29.5%), Sputum(12.5%) and bronchial wash (12.5%). In HIV positive patients, most
predominant sample was CSF (9.5%).
CHART 2: PERIOD OF IMMUNOSUPPRESSION FAVOURING
FUNGAL INFECTION
CHART 3: DISTRIBUTION OF SAMPLES COLLECTED FROM STUDY
POPULATION
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Table 4: Distribution and Categorization of IFI among suspected study
population(n=200)
Categories
Criteria Total
Renal
Transplant
Diabetes
Mellitus
(DM)
Renal
Transplant
& DM
Chemo
Therapy
(CT)
CT &
DM HIV n %
Proven 3(5%) 14(21%) 3(50%) 8(19%) 2(100) 5(22%) 35 17.5
Probable 9(15%) 27(40%) 1(17%) 7(16%) - - 44 22
Possible 47(80%) 26(39%) 2(33%) 28(65%) - 18(78%) 121 60.5
Total (%) 59(29.5) 67(33.5) 6(3) 43(21.5) 2(1) 23(11.5) 200 100
The above table shows that the incidence of  proven IFI was only 17.5%. Most of the
cases were under the category of possible IFI (60.5%).
Table 5: Predisposing factors for IFI among Renal Transplant recipients (n=65)
Predisposing factors Proven IFI Probable IFI Possible IFI Total n(%)
Hepatitis C virus (HCV) 2(11.7%) 1(5.88%) 14(82.3%) 17(26.1%)
Cytomegalovirus(CMV) - 2(16.6%) 10(83.3%) 12(18.4%)
Diabetes mellitus 1(25%) 1(25%) 2(50%) 4(6.15%)
Post Tx maintenance
hemodialysis
- 2(20%) 8(80%) 10(15.3%)
Neutropenia 1(7.69%) 2(15.3%) 10(76.9%) 13(20%)
Iron therapy& DM 2(100%) 0 0 2(3.07%)
Herpes simplex virus
(HSV)
- 2(28.5%) 5(7.42%) 7(10.76%)
Total 6(9.2%) 10(15.3%) 49(75.3%) 65(100%)
Among 65 post renal transplant patients, 6(9.2%) were proven IFI, 10(15.3%) were
probable IFI and 49(17.3%) were possible IFI. Diabetes mellitus patients with iron
therapy and HCV positivity appears to be the commonest risk factor for proven IFI.
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Table 6: Distribution of criteria for  Proven IFI (n=35)
Criteria KOH /HPE +ve Fungemia
Culture
of Sterile
Site
India Ink/ latex
agglutination
test
Total n=35
Renal Tx 3(8.5%) - - - 3(8.5%)
DM 11(31.4%) 2(5.7%) 1(2.8%) - 14(40%)
Renal Tx  &
DM
2(5.7%) 1(2.8%) - - 3(8.5%)
CT 7(20%) 1(2.8%) - - 8(22.8%)
CT & DM 2(5.7%) - - - 2(5.7%)
HIV 1(2.8%) - - 4(11.4%) 5(14.2%)
Total 26(74.2%) 4(11.4%) 1(2.8%) 4(11.4%) 35(100%)
Among the 4 accepted methods of approval of IFI, in our study most of the cases
showed positivity by KOH/HPE i.e 26(74.2%).
Table 7: Distribution of invasive mycoses among proven and
probable cases of IFI (n=79)
Incidence of Specific Mycoses No. %
Aspergillosis 33 16.5%
Candidiasis 30 15%
Hyalohyphomycosis 5 2.5%
Zygomycosis 4 2%
Cryptococcosis 4 2%
Phaeohyphomycosis 3 1%
Of 79 patients with proven & probable IFI,  Aspergillosis n=33(16.5%) was
most commonly encountered.
CHART 4: DISTRIBUTION AND CATEGORIZATION OF IFI
CHART  6: DISTRIBUTION OF CRITERIA FOR PROVEN IFI
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Table 8: Distribution of yeast and yeast like isolates among proven & probable
IFI & their frequency of isolation (n=34)
Species
Renal
Transplant
Diabetes
Mellitus
(DM)
Renal
Transplant
& DM
Chemo
Therapy
(CT)
CT
&
DM
HIV Total
n =34
Cryptococcus
neoformans
- - - - - 4
(80%)
4
(11.7%)
Candida
albicans
5
(55.5%)
9
(64%)
- 4
(100%)
- 1
(20%)
19
(55.8%)
Candida
tropicalis
2
(22.5%)
2
(14.5)
1
(50%)
- - - 5
(14.7%)
Candida
glabrata
1
(11%)
2
14.5%)
1
(50%)
- - - 4
(11.7%)
Candida
parapsilosis
1
(11%)
1
(7%)
- - - - 2
(5.8%)
Total 9(26.4%) 14(41.1%) 2(5.8%) 4(11.7%) 0 5(14.7%) 34
Among the Yeast (34) isolates Candida spp 30 (88.2%) was common among
study group. Most common species isolated was C.albicans 19 ( 55.8%  ), followed by
11  (32.3%  ) Non Candida albicans.  Most  common  among  NCA  was C.tropicalis 5
( 14.7% ) followed by C.glabrata 4  ( 11.7%) and C.parapsilosis 2( 5.8% ). Rest of the
4 (11.7%) were Cryptococcus neoformans , which was isolated only from HIV positive
patients.
CHART 7: DISTRIBUTION OF INVASIVE MYCOSES AMONG PROVEN
AND PROBABLE CASES OF IFI
CHART  8: DISTRIBUTION OF YEAST AND YEAST LIKE ISOLATES
AMONG PROVEN & PROBABLE  IFI
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Table 9: Distribution of Filamentous fungal isolates of IFI & their
frequency of isolation (n=45)
Species
Renal
Transplant
Diabetes
Mellitus (DM)
Renal
Transplant
& DM
Chemo
Therapy (CT) CT & DM HIV Totaln =45
Asp.fumigatus 2
(66.6%)
12
(44.4%)
- 5
(45.5%)
- - 19
(42.2%)
Asp.flavus - 3
(11.1%)
- 3
(27.2%)
2
(100%)
- 8
(17.7%)
Asp.terreus - 4
(14.8%)
- - - - 4
(8.8%)
Asp.niger - 1
(3.7%)
- - - - 1
(2.2%)
Asp.nidulans - 1
(3.7%)
- - - - 1
(2.2%)
Penicillium
spp
- 2
(7.4%)
- 1
(9%)
- - 3
(6.6%)
Fusarium
solani
- - - 2
(18.1)
- - 2
(4.4%)
Rhizopus
oryzae
- 1
(3.7%)
2
(100%)
- - - 3
(6.6%)
Absidia
corymbifera
- 1
(3.7%)
- - - - 1
(2.2%)
Curvularia
lunata
- 1
(3.7%)
- - - - 1
(2.2%)
Exserohilum
rostratum
- 1
(3.7%)
- - - - 1
(2.2%)
Dematiaceous
fungi
1
(33.3%)
1
(2.2%)
Total 3(6.5%) 27(58.6%) 2(4.3%) 11(23.9%) 2(4.3%) - 45
  Among the 45 Filamentous isolates, majority of fungi isolated were Aspergillus
spp 33 (73%), in particular Aspergillus fumigatus n=19 (42.2%).  And most of them
were from patients with uncontrolled DM i.e, 27(58.6%). One dematiaceous fungi
isolated from renal transplant recipient was not able to be identified.
CHART  9: DISTRIBUTION OF FILAMENTOUS FUNGAL ISOLATES OF IFI
CHART 10: INTERPRETATION OF FOLLOW UP OF THE STUDY CASES:
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Table 10: Distribution of yeast isolates  causing IFI in various samples
Specimen C.albicans C.tropicalis C.gladrata C.parapsilosis Cryptococcus
neoformans
No
growth
Urine(59) 9(15.2%) 5(8.4%) 2(3.2%) 2(3.2%) - 41(69%)
Drain /
Catheter(23)
1(4%) - - - - 22(96%)
CSF (19) - - - - 4(21%) 15(79%)
Pus(10) 2(20%) - - - - -
Blood (7) 3(43%) - 2(28.5%) - - 2(28.5%)
Gastric
lavage(6)
3(66%) - - - - 3(66%)
IV Catheter
tip(1)
1(100%) - - - - -
Above table shows that C.albicans(15.2%) was commonly reported  followed
by C.tropicalis(8.4%), C.glabrata(3.2%) and C.parapsilosis(3.2%) from urine
specimen. In blood, C.albicans 43% were reported followed by 28.5% of C.glabrata.
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Table 11: Distribution of filamentous fungi causing IFI in various samples:
Specimen A.fumigatus A.flavus A.terreus A.niger A.nidulans Penicillium F.solani Rhizopus
oryzae
Absisia
cormbifera
Curvularia
lunata
Exserohilm
rostratum
Unidentified
fungi
No
growth
Sputum
(25)
5(20%) 1(4%) - 1(4%) - - 2(8%) - - - 1(4%) - 15(60%)
Br. Wash
(25)
11(44%) 4(16%) 1(4%) - - 3(12%) - - - 1(4%) - - 5(20%)
Pus(10) - 1(10%) 1(10%) - - - - 1(10%) - - - 1(10%) 4(40%)
Pleural fl
(8)
1(12.5%) - 1(12.5%) - - - - - - - - - 6(75%)
BAL
(5)
2(40%) - 1(20%) - 1(20%) - - - - - - - 1(20%)
Ascitic fl.
(5)
- 1(20%) - - - - - - - - - - 4(80%)
FNAC
aspirate(5)
- 1(20%) - - - - - 2(40%) 1(20%) - - 1(20%)
Palatal
Scraping(2)
- - - - - - - - - - - - 2(100%)
Above table shows, that A.fumigatus was most commonly isolated from bronchial wash and sputum. Rhizopus oryzae was mostly isolated
from orbital bone lesions obtained by  FNAC aspiration.
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Table 12:  Results of minimum inhibitory concentration (MIC) by microbroth dilution method of Amphotericin B,
Itraconazole,Voriconazole and Fluconazole to yeast and yeast like fungus
Species Number
AMPHOTERICIN B ITRACONAZOLE VORICONAZOLE FLUCONAZOLE
S*
MIC
<1µg /
ml
R
MIC
>1µg/ml
Mean
MIC of
Sensitive
Isolates
(µg/ml)
S*
MIC
<1µg /
ml
R
MIC
>1µg/ml
Mean
MIC of
Sensitive
Isolates
(µg/ml)
S*
 MIC
<1µg / ml
R
MIC
>1µg/ml
Mean
MIC of
Sensitive
Isolates
(µg/ml)
S*
MIC
<8µg /
ml
R
MIC
>64µg/ml
Mean
MIC of
Sensitive
Isolates
(µg/ml)
Cryptococcus
neoformans
4 4
(100%)
- 0.0625 - - - 4
(100%)
- 0.125 4
(100%)
- 0.125
Candida
albicans
19 18
(94.8%)
1
(5.2%)
0.5 18
(94.8%)
1
(5.2%)
0.5 19
(100%)
- 0.25 18
(94.8%)
1
(5.2%)
0.5
Candida
tropicalis
5 5
(100%)
- 0.25 5
(100%)
- 0.25 5
(100%)
- 0.125 5
(100%)
- 0.25
Candida
parapsilosis
2 2
(100%)
- 0.125 2
(100%)
- 0.0625 2
(100%)
- 0.125 2
(100%)
- 0.0625
Candida
glabrata
4 4
(100%)
- 0.25 4
(100%)
- 0.5 4
(100%)
- 0.5 - 4
(100%)
-
S= Sensitive, R=Resistant
*Interpretive criteria currently not standardized. Studies show that for Yeast fungi MIC below 1µg/ml to Amphotericin B, Itraconazole &
Voriconazole and MIC below 8µg/ml to Fluconazole are associated with clinical cure. Most of the Yeast isolates in the study were sensitive
to all antifungal drugs tested and their MIC were in the range of  0.0313 to 0.125 µg/ml for Amphotericin B, 0.0625 to 0.5 µg/ml for
Itraconazole, 0.0625 to 0.5 µg/ml for Voriconazole and 0.0313 to 0.5 µg/ml for Fluconazole.
One C.albicans isolate has showed MIC in the resistance range for Amphotericin B, Itraconazole and Fluconazole, but sensitive to
Voriconazole. 100% resistance to Fluconazole was seen among C.glabrata.
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Table 13: Results of MIC by Agar dilution method of Amphotericin B, Itraconazole,Voriconazole and Fluconazole to yeast and yeast
like fungus
Species Number
AMPHOTERICIN B ITRACONAZOLE VORICONAZOLE FLUCONAZOLE
S* R Mean
MIC of
Sensitive
Isolates
(µg/ml)
S* R Mean
MIC of
Sensitive
Isolates
(µg/ml)
S* R Mean
MIC of
Sensitive
Isolates
(µg/ml)
S* R Mean
MIC of
Sensitive
Isolates
(µg/ml)
Cryptococcus
neoformans
4 4
(100%)
- 0.0625 - - - 1
(100%)
- 0.125 4
(100%)
- 0.0625
Candida
albicans
19 18
(94.8%)
1
(5.2%)
0.125 19
(100%)
- 0.125 19
(100%)
- 0.125 19
(100%)
- 0.125
Candida
tropicalis
5 5
(100%)
- 0.5 5
(100%)
- 0.25 5
(100%)
- 0.25 5
(100%)
- -
Candida
parapsilosis
2 2
(100%)
- 0.125 2
(100%)
- 0.0625 2
(100%)
- 0.0313 2
(100%)
- 0.125
Candida
glabrata
4 4
(100%)
- 0.125 4
(100%)
- 0.125 4
(100%)
- 0.125 - 4
(100%)
0.125
Most isolates were sensitive to Amphotericin B, Itraconazole and Voriconazole by Agar dilution method of detecting MIC. 5.2% of
C.albicans were resistance to Amphotericin B and 100% resistance to Fluconazole was seen among C.glabrata.
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Table 14: Results of MIC by E test method to yeast and yeast like fungus to Amphotericin B, Itraconazole and Fluconazole:
Species Number
AMPHOTERICIN B ITRACONAZOLE FLUCONAZOLE
S R Mean
MIC of
Sensitive
Isolates
(µg/ml)
S R Mean
MIC of
Sensitive
Isolates
(µg/ml)
S R Mean
MIC of
Sensitive
Isolates
(µg/ml)
Cryptococcus
neoformans
4 4
(100%)
- 0.0625 - - - 4
(100%)
- 0.0625
Candida albicans 19 18
(94.8%)
1
(5.2%)
0.125 19 - 0.125 19
(100%)
- 0.125
Candida tropicalis 5 5
(100%)
- 0.5 5
(100%)
- 0.25 5
(100%)
- 0.125
Candida
parapsilosis
2 2
(100%)
- 0.125 2
(100%)
- 0.0625 2
(100%)
- 0.0625
Candida glabrata 4 4
(100%)
- 0.125 4
(100%)
- 0.125 - 4
(100%)
-
Most of the isolates were sensitive to Amphotericin B and Fluconazole by Epsilometer test  and mean MIC range was from 0.0313 to
0.5µg/ml. 94.8% of Candida albicans were sensitive to Amphotericin B and 5.2% were resistant. 100% resistance was seen for Fluconazole
among C.glabrata. Universally 100% sensitivity was seen with Itraconazole among all isolates.
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Table 15: Results of Disc diffusion test for Yeast and Yeast like fungi for Amphotericin B, Itraconazole and Fluconazole:
Species Number
AMPHOTERICIN B ITRACONAZOLE FLUCONAZOLE
S (Zone
>15mm)
SDD/I(Zone
13-14mm)
R(Zone
<12mm)
S (Zone
>17mm)
SDD/I(Zone
14-16mm)
R(Zone
<13mm)
S (Zone
>19mm)
SDD/I(Zone
15-18mm)
R(Zone
<19mm)
Candida albicans 19 15
(79%)
2
(10.4%)
2
(10.4%)
17
(89.6%)
1
(5.2%)
1
(5.2%)
14
(73.6%)
3
(15.7%)
2
(10.4%)
Candida
tropicalis
5 5
(100%)
- - 5
(100%)
- - 4
(80%)
- 1
(20%)
Candida
parapsilosis
2 2
(100%)
- - 2
(100%)
- - 2
(100%)
- -
Candida glabrata 4 4
(100%)
- - 4
(100%)
- - - - 4
(100%)
S= SUSCEPTIBLE; SDD= SUSCEPTIBLE DOSE DEPENDENT; R= RESISTANT
79% of C.albicans were sensitive to Amphotericin B, 10.4% were resistant and 10.4% were susceptible dose dependent. All other isolates were sensitive
to Amphotericin B.
89.6% of C.albicans were sensitive to Itraconazole, 5.2% were susceptible dose dependent and 5.2% were resistant. All other isolates were sensitive to
Itraconazole.
Disc diffusion test using Fluconazole showed that73.6% of C.albicans were sensitive, 15.7% were susceptible dose dependent and 10.4% were resistant.
Among C. tropicalis 80% were sensitive and 20% were resistant. C.glabrata showed 100% resistance.  All C.parapsilosis were 100% sensitive.
71
Table 16: Comparison of Disk diffusion, E Test and Agar dilution of
Amphotericin B with Microdilution Reference Method to Yeast and
Yeast like Organisms:
Species Broth
dilution(S)
Disk diffusion E test Agar
Dilution
m M VM M VM  M VM
Cryptococcus
neoformans(4)
4 - - -  - - - -
Candida
albicans
(19)
18 2(10.4%) 1(5.2%) -  - - - -
Candida
tropicalis
(5)
5 - - -  - - - -
Candida
glabrata
(4)
4 - - -  - - - -
Candida
parapsilosis(2)
2 - - -  - - - -
m = minor error; M= Major error; VM= Very Major error
Interpretated as per the criteria given by A.Espinel –Ingroff et al:
Minor error(m): Shifts between susceptible and susceptible dose dependent or
between resistant and susceptible dose dependent
Major error(M): Isolate resistant by other methods but susceptible by broth dilution
Very Major error(VM): Broth dilution shows resistance and others show as sensitive
There is an 100% agreement between microbroth dilution, agar dilution and E test for
Amphotericin  B.  But  minor  error  of  10.4%  and  a  major  error  of  5.2%   was  seen
between broth dilution and disc diffusion test.
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Table 17:  Comparison of Disk diffusion, E Test and Agar dilution of Itraconazole
with Microdilution Reference Method to Yeast and Yeast like
Organisms:
Species Brothdilution(S)
Disk diffusion E test AgarDilution
m M VM M VM  M VM
Candida
albicans
(19)
18 1(5.2%) - -  - - - 1(5.2%)
Candida
tropicalis(5)
5 - - -  - - - -
Candida
glabrata
(4)
4 - - -  - - - -
Candida
parapsilosis(2)
2 - - -  - - - -
There is an 100% agreement seen between broth dilution and Etest for
itraconazole. But a very major error of 5.2% with C.albicans was seen between broth
and agar dilution and  5.2% of minor error seen between broth and agar dilution.
Table 18:Comparison of Agar dilution of voriconazole with Microdilution
Reference Method to Yeast and Yeast like Organisms:
Species Broth dilution(S)
Agar Dilution
M VM
Cryptococcus  neoformans(4) 4 - -
Candida albicans(19) 19 - -
Candida tropicalis(5) 5 - -
Candida glabrata(4) 4 - -
Candida parapsilosis(2) 2 - -
100% agreement was seen between broth dilution and agar diffusion for voriconazole.
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Table 19: Comparison of Disk diffusion, E test  and Agar dilution of Fluconazole
with Microdilution Reference Method to Yeast and Yeast like
Organisms:
Species Brothdilution(S)
Disk diffusion E test
Agar
Dilution
m M VM  M VM M VM
Cryptococcus
neoformans(4)
4 - - -  - - - -
Candida
albicans(19)
18 3(10.4%) 1(5.2%) - - 1(5.2%) -  1(5.2%)
Candida
tropicalis(5)
5 - - -  - - - -
Candida
glabrata(4)
4 - - -  - - - -
Candida
parapsilosis(2)
2 - - -  - - - -
On comparing broth dilution with disc diffusion showed a minor error of 10.4% and a
major error of 5.2%. On comparing agar dilution and E test with microbroth dilution
method showed a very major error of 5.2%.
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Table 20: Results of minimum inhibitory concentration(MIC) by microbroth
dilution method of Amphotericin B, Itraconazole, Voriconazole and Fluconazole
to filamentous fungus
Species Number
AMPHOTERICIN B Itraconazole Voriconazole
S*
MIC
<2 µg /
ml
R
MIC
>2
µg/ml
Mean
MIC of
Sensitive
Isolates
(µg/ml)
S*
MIC <8
µg / ml
R
MIC
>8
µg/ml
Mean
MIC of
Sensitive
Isolates
(µg/ml)
S*
 MIC
<8 µg /
ml
R
MIC
>8
µg/ml
Mean
MIC of
Sensitive
Isolates
(µg/ml)
Asp.fumigatus 19
18
(94.8%)
1
(5.2%)
0.25
17
(89.4%)
2
(10.4%)
0.0313
19
(100%)
- 0.25
Asp.flavus 8
8
(100%)
- 0.5
8
(100%)
- 0.125
8
(100%)
- 0.5
Asp.terreus 4 -
4
(100%)
-
4
(100%)
- 0.5
4
(100%)
- 0.5
Asp.niger 1
1
(100%)
- 0.125
1
(100%)
- 0.125
1
(100%)
- 0.125
Asp.nidulans 1
1
(100%)
- 1
1
(100%)
- 0.5
1
(100%)
- 0.5
Penicillium
spp 3
3
(100%)
- 0.5
3
(100%)
- 0.125
3
(100%)
- 0.125
Fusarium
solani 2 -
2
(100%)
- -
2
(100%)
-
2
(100%)
- 0.5
Rhizopus
oryzae 3
3
(100%)
- 0.5
3
(100%)
- 0.25
3
(100%)
- 0.5
Absidia
corymbifera 1
1
(100%)
- 0.5
1
(100%)
- 0.25
1
(100%)
- 0.125
Curvularia
lunata 1
1
(100%)
- 0.5
1
(100%)
- 0.5
1
(100%)
- 0.5
*Interpretive criteria currently not standardized. Studies show MIC of
Amphotericin B below 2µg/ml and MIC of  Itraconazole and Voriconazole below
8µg/ml to filamentous fungi associated with clinical cure.
Most of the  isolates in the study were sensitive to Amphotericin B and were in
the  MIC  range  of  0.125  to  1µg/ml  for  Filamentous  forms.  5.2%  of Asp.fumigatus
isolate has shown MIC in resistant range. All Asp.terreus and Fusarium solani showed
100% resistance to Amphotericin B
Most of the  isolates in the study were sensitive to Itraconazole and were in the
MIC range of 0.125 to 0.5µg/ml for Filamentous forms. 10.4% of Asp.fumigatus  has
shown MIC in resistant range. 100% resistance to itraconazole was seen among
Fusarium solani.
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Table 21: Results of MIC by Agar Dilution method of Amphotericin B,
Itraconazole and Voriconazole to Filamentous fungi:
Species No.
AMPHOTERICIN B ITRACONAZOLE VORICONAZOLE
S* R
Mean
MIC of
Sensitive
Isolates
(µg/ml)
S* R
Mean
MIC of
Sensitive
Isolates
(µg/ml)
S* R
Mean
MIC of
Sensitive
Isolates
(µg/ml)
Asp.fumigatus 19 19
(100%)
- 0.25 18
(94.8%
1
(5.2%)
0.0313 19
(100%)
- 0.0313
Asp.flavus 8 8
(100%)
- 0.5 8
(100%)
- 0.25 8
(100%)
- 0.125
Asp.terreus 4 - 4
(100%)
- 4
(100%)
- 0.5 4
(100%)
- 0.25
Asp.niger 1 1
(100%)
- 0.125 1
(100%)
- 0.125 1
(100%)
- 0.125
Asp.nidulans 1 1
(100%)
- 0.5 1
(100%)
- 0.5 1
(100%)
- 0.125
Penicillium
spp
3 3
(100%)
- 0.5 3
(100%)
- 0.125 3 - 0.125
Fusarium
solani
2 - 2
(100%)
- - 2
(100%)
- 2
(100%)
- 0.25
Rhizopus
oryzae
3 3
(100%)
- 0.5 3
(100%)
- 0.25 3
(100%)
- 0.25
Absidia
corymbifera
1 1
(100%)
- 0.25 1
(100%)
- 0.25 1
(100%)
- 0.25
Curvularia
lunata
1 1
(100%)
- 0.5 1
(100%)
- 0.5 1
(100%)
- 0.5
Most isolates were sensitive to Amphotericin B, Itraconazole and Voriconazole by
Agar dilution method of detecting MIC. 100% resistance was seen among F.solani and
Asp.terreus for Amphotericin B, 100% of F.solani & 5.2% of Asp.fumigatus were
resistant to Itraconazole.
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Table 22: Results of MIC by E-test method  of  Amphotericin B
and Itraconazole to Filamentous fungi:
Species
Number
Amphotericin B Itraconazole
S R
Mean
MIC of
Sensitive
Isolates
(µg/ml)
S R
Mean
MIC of
Sensitive
Isolates
(µg/ml)
A.fumigatus 19 19
(100%)
- 0.0313 19
(100%)
- 0.0313
A.flavus 8 8
(100%)
- 0.5 8
(100%)
- 0.25
A.terreus 4 - 4
(100%)
- 4
(100%)
- 0.5
         A.niger 1 1
(100%)
- 0.0313 1
(100%)
- 0.125
A.nidulans 1 1
(100%)
- 0.5 1
(100%)
- 0.5
Penicillium spp 3 3
(100%)
- 0.5 3
(100%)
- 0.125
F. solani 2 - 2
(100%)
- 2
(100%)
- 0.5
Rhizopus oryzae 3 3
(100%)
- 0.5 3
(100%)
- 0.25
Absidia corymbifera 1 1
(100%)
- 0.25 1
(100%)
- 0.25
Curvularia lunata 1 1
(100%)
- 0.5 1
(100%)
- 0.5
All isolates were sensitive to Amphotericin B and Itraconazole by Epsilometer
test  and MIC range was from 0.0313 to 0.5. 100% resistance to Amphotericin B seen
among Asp.terreus. F.solani showed 100% resistance to both Amphotericin B and
Itraconazole by E test.
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Table 23: Results of Disc diffusion method of Amphotericin B
and Itraconazole to filamentous fungi
Species Num
ber
Amphotericin B Itraconazole
S
(Zone
>15mm)
SDD/I
(Zone
13-14
mm)
R
(Zone
<12mm)
S
(Zone
>17mm)
SDD/I
(Zone
14-16
mm)
R
(Zone
<13mm)
A.fumigatus 19 13
(68.4%)
3
(15.7%)
3
(15.7%)
14
(73.6%)
2
(10.5%)
3
(15.7%)
A.flavus 8 6
(75%)
1
(12.5%)
1
(12.5%)
5
(62.5%)
1
(12.5%)
2
(25%)
A.terreus 4 - - 4
(100%)
3
(75%)
- 1
(25%)
      A.niger 1 1
(100%)
- - 1
(100%)
- -
A.nidulans 1 1
(100%)
- - 1
(100%)
- -
Penicillium spp 3 3
(100%)
- - 2
(66.6%)
1
(33.3%)
-
F. solani 2 - - 2
(100%)
- - 2
(100%)
Rhizopus
oryzae
3 3
(100%)
- - 3
(100%)
- -
Absidia
corymbifera
1 1
(100%)
- - 1
(100%)
- -
Curvularia
lunata
1 1
(100%)
- - 1
(100%)
- -
S= SUSCEPTIBLE; SDD= SUSCEPTIBLE DOSE DEPENDENT; R= RESISTANT
68.4% Asp.fumigatus were sensitive, 15.7% were resistant and 15.7% were susceptible
dose dependent. 75% of the Asp.flavus were sensitive, 12.5% were resistant and 12.5%
were susceptible dose dependent. Fusarium spp and Asp.terreus showed 100%
resistance to Amphotericin B. All other isolates were universally sensitive to
Amphotericin B.
Of 19 Asp.fumigatus, 73.6% were sensitive,10.5% were susceptible dose dependent and
15.7% were resistant.  Out of 8 Asp.flavus tested 62.5% were susceptible, 12.5% were
susceptible dose dependent and 25% were resistant. All other isolates were sensitive to
Itraconazole.
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Table 24: Comparison of Disk diffusion, E Test and Agar dilution of Amphotericin B with
Microdilution Reference Method to Filamentous fungi:
Species Broth
dilution(S)
Disk diffusion E test Agar
Dilution
m M VM  M VM  M VM
A.fumigatus(19) 18 3(15.6%) 2(10.4%) - - 1(5.2%) - 1(5.2%)
A.flavus(8) 8 1(12.5%) 1(12.5%) - - - - -
A.terreus(4) - - - - - - - -
A.niger(1) 1 - - - - - - -
A.nidulans(1) 1 - - - - - - -
Penicillium
spp(3)
3 - - - - - - -
Fusarium
solani(2)
- - - - - - - -
Rhizopus
oryzae(3)
3 - - - - - - -
Absidia
corymbifera(1)
1 - - - - - - -
Curvularia
lunata(1)
1 - - - - - - -
m = minor error; M= Major error; VM= Very Major error
Interpretated as per the criteria given by A.Espinel –Ingroff et al:
Minor error(m): Shifts between susceptible and susceptible dose dependent or
between resistant and susceptible dose dependent
Major error(M): Isolate resistant by other methods but susceptible by broth dilution
Very Major error(VM): Broth dilution shows resistance and others show as sensitive
Very major error of 5.2% in A.fumigatus was seen in both agar dilution and E test  on
comparing with broth dilution for amphotericin B.15.6% and 12.5% of minor error and
12.5% of major error each was seen among A.fumigatus and A.flavus respectively with
disc diffusion method when compared to broth dilution method.
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Table 25:Comparison of Disk diffusion, E Test and Agar dilution of Itraconazole
with Microdilution Reference Method to Filamentous fungi:
Species Broth
dilution
(S)
Disk diffusion E test Agar Dilution
m M VM M VM M VM
A.fumigatus(19) 17 2(10.4%) 1(5.2%) -  - 2(10.4%) - 2(10.4%)
A.flavus(8) 8 1(12.5%) 2(25%) -  - - - -
A.terreus(4) 4 - - -  - - - -
A.niger(1) 1 - - -  - - - -
A.nidulans(1) 1 - - -  - - - -
Penicillium
spp(3)
3 1(33.3%) - -  - - - -
Fusarium
solani(2)
- - - -  - - - -
Rhizopus
oryzae(3)
3 - - -  - - - -
Absidia
corymbifera(1)
1 - - -  - - - -
Curvularia
lunata(1)
1 - - -  - - - -
Very major error of 10.4% in A.fumigatus was seen in both agar dilution and E
test on comparing with broth dilution for itraconazole.10.4% ,12.5% and 33.3% of
minor error was seen among A.fumigatus, A.flavus and Penicillium spp respectively and
5.2% and  25% of  major  error  was  seen  among A.fumigatus and A.flavus respectively
with disc diffusion method when compared to broth dilution method.
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Table 26: Comparison of Agar dilution for voriconazole with Microdilution
Reference Method for Filamentous fungi:
Species Broth dilution(S)
Agar Dilution
M VM
A.fumigatus(19) 18 - -
A.flavus(8) 8 - -
A.terreus(4) 4 - -
A.niger(1) 1 - -
A.nidulans(1) 1 - -
Penicillium spp(3) 3 - -
Fusarium solani(2) 2 - -
Rhizopus oryzae(3) 3 - -
Absidia corymbifera(1) 1 - -
Curvularia lunata(1) 1 - -
There is no discrepancy seen between broth dilution and agar dilution for
voriconazole in filamentous fungi.
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Table 27: Prognostic interpretation of the follow up of study cases:
Follow Up
Proven IFI
(n=35)
Probable IFI
(n=44)
Possible IFI
(n=121) Total (%)
Cured 28(80%) 20(45.5%) 89(73.5%) 137(68.5%)
Relapse 2(5.7%) 16(36%) 20(16.5%) 38(19%)
Death 5(14.2%) - - 5(2.5%)
Lost  To Follow
Up
- 8(18.5%) 12(9.9%) 20(10%)
The overall   mortality  of  2.5% cases  was  seen  in  the  study.  All  of  them were
proven IFI.
Mortality was seen among cancer patients on chemotherapy with neutropenia
due to Candidemia and invasive aspergillosis,  AIDS patient with a low CD4 count of
<34cells/µl and in uncontrolled DM patients with Diabetic keto acidosis due to
Rhizopus oryzae with grave complication like cavernous sinus thrombosis.
Relapse was commonly seen among  probable IFI(36%). Cure rate of 73.5%
was seen among possible IFI.
PATIENT WITH COMPLICATION OF CAVERNOUS SINUS
THROMBOSIS
CT SCAN SHOWING HALO SIGN IN IA PATIENT
10% KOH- BROAD PAUCI
SEPTATE HYPHAE WITH OBTUSE
ANGLE BRANCHING
10% KOH- SLENDER PHAEOID
SEPTATE HYPHAE
CT SCAN SHOWING CAVERNOUS SINUS THROMBOSIS(RIGHT
SIDE PREDOMINANT)
CFW SHOWING PAUCISEPTATE
HYPHAE
INDIA INK SHOWING
CAPSULATED BUDDING YEAST
10% KOH- SLENDER SEPTATE
HYPHAE WITH ACUTE ANGLE
BRANCHING
10% KOH- BROAD
PAUCISEPTATE
HYPHAE WITH
SPORANGIA
H&E SHOWING SEPTAL HYPHAL
FORMS
GMS SHOWING ASEPTATE
HYPHAL FORMS
GRAM STAIN SHOWING
BUDDING YEAST CELLS
GRAM STAIN SHOWING
CAPSULATED CRYPTOCOCCUS
SPP
CAFFEIC ACID AGAR SHOWING BROWN
COLOURED CRYPTOCOCCUS COLONIES
UREASE TEST POSITIVE
LAT CARD SHOWING CLUMPING  FOR CRYPTOCOCCAL ANTIGEN
GERM TUBE TEST- C.ALBICANS SHOWING GERM TUBE
CHROMAGAR SHOWING LIGHT
GREEN C.ALBICANS
CHROMAGAR SHOWING STEEL
BLUE C.TROPICALIS
FERMENTATION OF
C.ALBICANS
ASSIMILATION OF C.ALBICANS
ASPERGILLUS FLAVUS
ASPERGILLUS TERREUS
ASPERGILLUS FUMIGATUS
ASPERGILLUS NIDULANS- SDA PLATE SHOWING PRESENCE OF
PURPLE PIGMENT ON THE REVERSE
LPCB MOUNT SHOWING
COLUMNAR CONIDIAL HEADS
AND A SINGLE HULLE CELL
CLEISTOTHECIUM
SURROUNDED BY HULLE
CELLS
ASPERGILLUS NIGER
ADHESIVE TAPE PREPARATION WITH KOH SHOWING  BROWN
COLOURED CLEISTOTHECIA (LEFT) AND PURPLE COLOURED
ASCOSPORES DUE TO REACTION WITH KOH (RIGHT)
RHIZOPUS ORYZAE- UNBRANCHED SPORANGIOPHORE WITH
NODAL RHIZOIDS
PENICILLIUM SPP
ABSIDIA CORYMBIFERA WITH APOPHYSIS
FUSARIUM SOLANI WITH PINK DIFFUSABLE PIGMENT
ON SDA TUBE
CURVULARIA LUNATA
EXSEROHILUM ROSTRATUM – BLACK PIGMENTATION IN OBVERSE
AND REVERSE
AGAR DILUTION METHOD OF AMPHOTERICIN B
DISC DIFFUSION METHOD FOR YEAST LIKE
AND FILAMENTOUS FUNGI
E TEST – AMPHOTERICIN B
FOR A.FLAVUS
E TEST – AMPHOTERICIN B  FOR
A.TERREUS
E TEST FLUCONAZOLE FOR
CANDIDA SPP
E TEST – ITRACONAZOLE
FOR A.NIGER
MIC BY BROTH MICRODILUTION OF ITRACONAZOLE TO
FILAMENTOUS FUNGI
MIC BY BROTH MICRODILUTION OF VORICONAZOLE TO
FILAMENTOUS FUNGI
MIC BY BROTH MICRODILUTION OF AMPHOTERICIN B TO
CRYPTOCOCCUS SPP
MIC BY BROTH MICRODILUTION OF FLUCONAZOLE TO CANDIDA SPP
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DISCUSSION
Invasive Fungal Infection (IFI) is increasingly recognized among patients with
immunocompromised state[3] .The importance is due to the morbidity and mortality
caused by IFI. This study was conducted among 200 cases of immunocompromised
patients with signs and symptoms suggestive of IFI. Patients selected under the study
were those on chemotherapy for malignancy, renal transplant recipient on
immunosuppressive therapy, patients with Acquired immune deficiency syndrome
(AIDS) and Diabetes mellitus. The study was conducted at the Institute of
Microbiology, Madras medical college & RGGGH, Chennai-3 for a period of one year
from September 2011 to August 2012.
Most of the patients affected by IFI in this study (table 1) were in the age group
of 31-40(26%), followed by equal number of distribution among 21-30 & 41-50 age
group(22%). Among the study population,  majority of the patients were males (73%).
Wald et al, in his  study on IFI among bone marrow transplant patients showed
increased incidence among >40years age group with predominance noted among
males(69.4%)[92] . Marr et al, has also made similar observation that IFI was more
common among >40years(53%) with male(61%) predominance in stem cell transplant
recipients[93] .Similar findings have been recorded by Kontoyiannis et al  showed
median age of the patients with IFI was 49years and 60% were males[94].
Among immunocompromised patients, median time for development of IFI was
1-10 years (table 2). As the duration of immunocompromised state  increases,
susceptibility to infection also increases. This finding is similar to Kontoyiannis et al,
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who found a median duration for development of IFI in transplantation recipients of
135days [94] .
             Majority of patients of IFI presented with symptoms presented with urinary
tract and respiratory tract infections, therefore most samples collected were urine,
sputum, bronchial wash and bronchoalveolar lavage (table 3). Pagano et al, studied
patients with IFI  and reported most common site for infection as lung(56%)[95] .
Among the 200 cases in our study, 79(39.5%) showed fungal growth.
According to EORTC criteria among these 79 patients who showed fungal
growth,17.5% were proven and 22% were probable and rest 60% were possible IFI
(table 4). Siok-Ying lee et al reported a prevalence of IFI in hematological patients in
Singapore of 30.8% proven, 48.7% probable and 20.5% possible IFI [96] . Kontoyiannis
et  al,  studied on patients with IFI for a period of 5 years reported 56% of cases were
proven and 44% were to be probable IFI[94] .
In our study, (table 4) 20.8% of  proven IFI  and  40.2% of probable IFI were
among patients with uncontrolled diabetes mellitus (DM). Diabetes is a common
metabolic disorder with significant morbidity and mortality, and is commonly
considered as a risk factor of mycoses[3,97,98] .Usually  in  these  patients,  the  most
common fungal  invasion  are  those  of   the  urinary  tract  and  the  respiratory  tract.  The
reason for increased incidence and susceptibility is due to impaired phagocyte function,
such as adherence, chemotaxis, phagocytosis, and bactericidal activity in patients with
poor metabolic control[3,99,100]. This finding in our study is similar to observations made
by Jahromi and Khaksar et al,who isolated 28.4% of fungal infections among diabetic
patients[3].
84
Next  to  DM,  the  second  risk  factor  with  major  incidence  of  proven  IFI  was
among malignant patients on chemotherapy (18.6%). Prolonged neutropenia in these
patients acts as a predisposing factor, which suggests that the neutrophils have a major
role in host defence against fungal infections. Host defence depends mostly on the
phagocytic and oxidative activities of neutrophils, monocytes, and macrophagesThis
finding  of  our  study  correlates  with  Jahromi  and  Khaksar et al who reported 14.8%
among neutropenic patients[3] .
In our study among renal transplant recipients(n=65), Hepatitis C virus(26.1%)
was the predominant predisposing factor for IFI. Fabrizi et al. showed that positive
anti-HCV antibody status was a significant risk factor for fungal infection and death
after renal transplantation with a relative risk of 1.79 and 1.56 respectively[101] .
In  this  study,  Proven  IFI  is  defined  by  Direct  KOH  mount  and  /  or  HPE
positivity, fungemia in blood, India ink preparation or Antigen test positivity and
culture positive from sterile site. Among  proven IFI cases(n=35), 74.3% were detected
by KOH/HPE(table 6).
Invasive aspergillosis was the most common IFI (16.5%), followed by invasive
candidiasis (15%), hyalohyphomycosis due to Penicillium spp and Fusarium spp
(2.5%). Zygomycosis and Cryptococccosis were responsible for 2% cases of IFI(table
7). The presence of hyphal elements in the direct KOH mount in all the specimens
proven the clinical significance of our isolates. Our study finding is very similar to
Wald et al [92] and Marr et al [102]  who reported Aspergillus spp as the most common
etiological agent isolated followed by Candida spp. But, our results are in contrast to
the observation made by Kauffman et al[103] and Chakrabarti et al[1] who showed
Invasive Candidiasis as the most common invasive mycotic infection across India.
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Enoch et al [113] studied on IFI in Great Britain and Maertens et al [104] in Belgium
showed similar findings.
Candida spp are usually colonizers, so if isolated their clinical significance
needs to be defined. Candida spp from blood or on repeated isolation is taken as
pathogen. In our study, among invasive candidiasis, Candida albicans was  the  most
common organism(55.8%), followed by Candida tropicalis(14.7%), Candida
glabrata(11.7%) and Candida parapsilosis (5.8%)(table 8).
B George et al [105] and Pagano et al [106] reported Candida albicans as most
common isolate among  Candida spp which is almost similar to the results of the
present study.
The most common Candida spp isolated from blood culture were
C.albicans(43%) and C.glabrata(28.5%)(table 10). The incidence of candidemia gives
similar  reports  worldwide.  In  the  study  done  by  Tortorano  et  al[107],  main  agent  of
candidemia was C. albicans(58.5%) followed by C.glabrata (12.8%). A study by Trick
et al reported C. albicans  (59%) and C.glabrata (12%) from blood cultures of patients
on chemotherapy with suspected IFI[108]. Richet et al  reported C. albicans (53%)
followed by C.glabrata (11%) in blood culture[109]. Similar to our study, all other
studies also reported C.albicans as the leading pathogen followed by C.glabrata in
blood culture.
Harvey et al[110] studied on transplant patients and reported an isolation rate of
(58%) C.albicans followed by (25%) C.tropicalis and (15%) C.parapsilosis. In another
study  by  Chakrabarti  et  al,   on  immunocompromised  patients  with  suspected  IFI  the
common isolates from blood culture were C.albicans(50%), C.gulliermondii(17%) and
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C.tropicalis(8%)[111] .  In our study we isolated C.glabrata as second leading pathogen
in Candidemia whereas in above studies it was either C.tropicalis or C.gulliermondii.
In the present study from urine samples we isolated C. albicans (15.2%) as the
most common isolate followed by C. tropicalis (8.4%), C. glabrata (3.2%) and
C.parapsilosis(3.2%) (table 10). Study by Zarrin et al, among immunocompromised
patients reported an isolation rate of C. albicans (53.3%), followed by C. glabrata
(24.4%), C. tropicalis (3.7%), C. krusei (2.2%)[112].
The   majority  of  the Aspergillus spp isolated were Aspergillus
fumigatus(42.2%), followed by Aspergillus flavus (17.7%), Aspergillus terreus(8.8%),
Aspergillus niger and Aspergillus nidulans (2.2%)(table 9) from respiratory tract
specimens(table11). The number of non-Aspergillus moulds isolated were 12(15.2%)
[(table 9) which included Pencillium spp(6.6%), Rhizopus oryzae (6.6%), Fusarium
solani(4.4%), Adsidia corymbifera(2.2%)]. The dematiaceous mould involved in
disease were Curvularia lunata(2.2%), Exserohilum rostratum(2.2%) and one
unidentified dematatious fungi. Kontoyiannis et al [94] and  Siok  –  Ying  Lee   et  al[96]
have shown in their studies that among Aspergillus spp, Aspergillus fumigatus was the
most common species isolated from lung specimen. Their finding correlates with our
study report(table 11).
Due to the life threatening nature of invasive fungal infections and reports of
drug resistance, antifungal susceptibility testing(AST) for  pathogens are very
important.The primary objective of AST is to predict the impact of administration of
the tested agent on the outcome of infection caused by the tested organism.
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19 isolates of Candida albicans,5 of C.tropicalis,4 of C.glabrata and 2 of
C.parapsilosis were taken for antifungal susceptibility testing for Amphotericin B,
Itraconazole, Fluconazole and Voriconazole(table 12-15) by broth dilution, agar
dilution, E test and disc diffusion methods. All Non Candida albicans (NCA) showed
universal sensitivity to all antifungals tested except C.glabrata which showed complete
resistance  to  Fluconazole  alone.  This  may  be  due  to  intrinsic  resistance  exhibited  by
few strains of C.glabrata[42]
In our present study, C.albicans showed 5.2% resistance to Amphotericin B,
Itraconazole  and  Fluconazole  by  broth  dilution  method.  Agar  dilution  &  E  test  gave
equally similar results to Amphotericin B but 5.2% of very major error was seen
between broth and agar dilution to itraconazole and fluconazole(table 16-19).
A   study  with Candida spp by  Iatta  et  al  using  E  test  of  Amphotericin  B,
Itraconazole, Fluconazole and voriconazole gave a comparable results similar to that of
broth dilution method.[113] Barchiesia et al showed that broth microdilution and agar
dilution methods are equally good in testing Candida spp.[114]
But the present study showed 10.4% resistance to amphotericin B, 5.2% to
itraconazole and 10.4% to fluconazole was reported in C.albicans by disc
diffusion(DD) method. A discrepancy of 5.2% was seen between DD and broth dilution
procedure(table 16-19).
In a study by Goel et al which showed 95.53% of the Candida isolates to be
sensitive to fluconazole, a discrepancy between DD method and broth micro dilution
method was noted in 4.47% strains of C.albicans.[115]
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All  the  4 Cryptococcus neoformans isolates  in  this  study  were  tested  by  broth
dilution, agar dilution and E test showed 100% sensitivity to Amphotericin B,
Fluconazole and Voriconazole(table 16-19). AST to Itraconazole was not done since it
does not cross blood brain barrier. As  disc diffusion method is not recommended for
Cryptococcus spp it was not done. Archibald et al, studied the susceptibility pattern of
C.neoformans and reported 100% sensitivity to various antifungal agents.[116]
In our study,19 isolates of Aspergillus fumigatus, 8 of A.flavus,4 of A.terreus,3
each of Penicillium spp and Rhizopus oryzae,2 of Fusarium solani, and 1 each of
A.niger, A.nidulans, Absidia corymbifera and Curvularia lunata were taken for
antifungal susceptibility testing for Amphotericin B, Itraconazole and Voriconazole
(table 20-23). All the tested isolates were universally sensitive to Voriconazole by broth
dilution method and agar dilution method with no discrepancy (table 26).
All isolates were mostly sensitive to Amphotericin B by broth dilution method
except 5.2% of A.fumigatus which showed resistance. But 100% sensitivity to
amphotericin B was seen by agar dilution and E test methods for all filamentous fungi.
Therefore  a discrepancy of 5.2% was seen in agar dilution & E test on comparing with
broth dilution method((table 24). All isolates of A.terreus and Fusarium solani showed
100% resistance to Amphotericin B(table 20), since they exhibits intrinsic resistance to
the drug[42] .On testing with itraconazole, the results obtained by agar dilution & E test
method was comparable to that of microbroth dilution method for all tested isolates but
discrepancy of 10.4% was observed(table 25).
In a study carried out by Theres et al., it was observed that agar dilution method
is more easy and cost  effective for the susceptibility testing of filamentous fungi over
broth dilution method[ 117].
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Filamentous fungi isolated in the study showed 68.4% & 73.6% sensitivity was
seen  to  Amphotericin  B  and  itraconazole  respectively  by  disc  diffusion  method.  The
percentage of major (15.6%) error obtained by using Amphotericin B was found to be
much higher when compared to itraconazole(5.2%) by disc diffusion method .
Therefore, Amphotericin B discs should be used with caution in testing filamentous
fungi (table 24,25).
Soraino et al., showed the advantage of disc diffusion method over other
methods such as broth dilution or E test for voriconazole susceptibility testing of
Aspergillus. Only few reports are available on comparative analysis of disc diffusion
and broth dilution method for susceptibility testing of filamentous fungi[118].
Although broth dilution method is the recommended standard method suggested
by CLSI, this method is associated with some technical drawbacks such as cumbersome
procedure, time consuming, technically demanding with poor end point precision
particularly when fungistatic agents such as azoles are tested. While on the other hand
disc diffusion method is easy to perform, rapid and cost effective, so they are used for
the routine antifungal susceptibility testing of filamentous fungi in the clinical
laboratory. But Amphotericin B discs should be used with caution[119].
Lesser the time taken for results of AST better would be the therapeutic
outcome of infections caused by fungal pathogens.
Follow  up  was  done  for  all  the  patients  included  in  the  study  but  during  the
study period few patients expired. Overall mortality rate was 2.5%(table 27).  Most of
them were  from proven  IFI.  One  the  major  risk  factor  for  mortality  in  the  study  was
uncontrolled DM with ketoacidosis (40%) due to extension of Rhizopus oryzae from
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nasal mucosa to turbinate bone into the brain causing infarct and cavernous sinus
thrombosis. The other major risk factor was patients on chemotherapy (40%) due to
Candidemia caused by drug resistant C.albicans & disseminated aspergillosis due to
Asp.fumigatus.  mortality was also seen in  AIDS patient(20%)  with a low CD4 count
of 34 cells/µl.
United states data shows that in 1980 IFI was responsible for 828 deaths and
was the 10th most predominant cause of fatal infection. However in 1997 the number of
mycosis related deaths had risen to 2370 and was the seventh most prevalent terminal
infectious disease [120,121] .
A  study  done  by  Martino  et  al[93] and   Kontoyiannis  et  al[94]  on  patients  with
Candidemia showed a mortality rate of 8.3% and 11.5% respectively. Mortality rate of
36% due to Aspergillosis was reported by Jantunen et al [122] .
Strong suspicion, meticulous specimen collection & preparation and further
studies  with  a  long  period  of  follow  up  and  a  large  study  population  are  required  to
analyze the impact of fungi in etiopathogenesis of invasive fungal infections.
SUMMARY
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SUMMARY
? 200 patients who complied with the inclusion criteria were included under the
study. The most common age group of the study population was 31 to 40 years
(26%) and males were predominant(73%).
? Incidence of IFI occurs mostly after a prolonged period of immunosuppresion
of 1-10 years(77%)
? Most frequently encountered samples in this study were urine (29.5%) and
sputum (12.5%).
? Most of the IFI cases fall under the category of Possible IFI(60.5%)
? 17.5% were under the category of Proven IFI, mostly identified by KOH and/ or
HPE (74.2%).
? The rate of invasive fungal infection (proven and probable) in this present study
was 39.5%.
? Among the cases which showed fungal growth, Diabetes mellitus was the most
predominant risk factor encountered in 33.5% of cases.
? Among the 65 renal transplant recipients under the study, 26.1% were HCV
positive and in them 11.7% had proven IFI,5.88% had probable IFI and 21.5%
had possible IFI.
? Etiological agents were identified in 79(39.5%) of infected patients.
? Aspergillosis was most commonly encountered(16.5%), followed by
Candidiasis(15%) as etiological agents of IFI.
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? Among filamentous fungi A.fumigatus (42.2%) was the most common pathogen
isolated.
? Among Yeast like fungi C.albicans (55.8%)  was  the  most  common  pathogen
isolated.
? All isolates were sensitive to Voriconazole by broth microdilution and agar
dilution
? Antifungal susceptibility testing by microbroth dilution to yeast like fungi,
showed that 5.2%  of C.albicans was resistant to amphotericin B, itraconazole
and fluconazole.
? All non Candida albicans isolates were sensitive to all antifungals except
C.glabrata which showed resistance to fluconazole.
? No discrepancy was noted between microbroth dilution, agar dilution and E test
for Amphotericin B. But a major error of 5.2%  was seen between broth dilution
and disc diffusion test for Candida spp.
? Discrepancy of 5.2% was seen between microbroth dilution and agar dilution
for itraconazole and fluconazole.
? 100%  agreement  was  seen  with  microbroth  dilution  and  agar  dilution  for
voriconazole to yeast like fungi.
? Cryptococcus neoformans was mostly isolated from AIDS patients and were
100% sensitive to all antifungals.
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? Asp.fumigatus showed 5.2% and 10.4% of resistance to Amphotericin B and
itraconazole respectively by microbroth dilution method.
? Discrepancy of 5.2% and 10.4% was seen on comparing microbroth dilution
with agar dilution & E test to Amphotericin B and itraconazole respectively to
Asp.fumigatus in filamentous fungi.
? Discrepancy of 10.4% and 5.2% was seen on comparing microbroth dilution
with  disc  diffusion  to  Amphotericin  B  and  itraconazole  respectively  in
filamentous fungi.
? 100%  agreement  was  seen  between  broth  dilution  and  agar  dilution  for
voriconazole for filamentous fungi.
? Mortality rate encountered was 2.5% and all the cases had proven IFI.
CONCLUSION
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CONCLUSION
The present study was done on 200 suspected invasive fungal infection(IFI)
cases which  showed that majority of  patients  were in  the  age  group  of  31 to 40
years and they were predominantly males. Most of them had urinary and respiratory
tract infections following a prolonged period of immunosuppresion ranging from 1-10
years.
On categorization 17.5% had proven IFI, which was identified in majority of the
cases HPE and / or KOH. Uncontrolled diabetes mellitus was the comorbid risk factor
for IFI.
Etiological agent was identified in 39.5% of infected patients. Aspergillosis
caused by Asp.fumigatus was the leading cause for IFI followed by Candidiasis caused
by C.albicans.
Antifungal susceptibility test by microbroth dilution, agar dilution, E test and
disc diffusion methods to amphotericin B, itraconazole, fluconazole and voriconazole
showed equally similar results for most of the isolates. Few discrepancies were seen
among A.fumigatus and C.albicans mostly by disc diffusion method.
Proven IFI was life threatening and mortality was seen 2.5% of cases.
Due to the evolving nature of the epidemiology of  invasive fungal infections in
immunocompromised persons, continued research and surveillance are essential to
optimize the prevention and therapy of IFI in them.
BIBLIOGRAPHY
1) Arunaloke Chakrabarti, Shivsekhar Chatterjee, MR Shivprakash. Overview of
Opportunistic Fungal Infections in India. J.Med.Mycol 2008;49:165-72
2) Census of India.Office of the census control and registrar general of India.
http://www.censusindia.gov.in/Census_Data_2001/India_at_glance
3) Iran  Shahindokht  Bassiri  Jahromi  and  Ali  Asghar  Khaksar, Deep-Seated
Fungal Infections in Immunocompromised Patients in Medical Mycology
Department, Pasteur Institute of Iran, Tehran, Iran Iranian Journal Of Allergy,
Asthma And Immunology 2005; 4(1) :27
4) Rosemary A. Barnes. Early diagnosis of fungal infection in
immunocompromised patients JAC 2008
5) Lamagni TL, Evans BG, Shigematsu M. Emerging trends in the epidemiology
of invasive mycoses in England and Wales (1990–9). Epidemiol Infect 2001;
126: 397–414.
6) Kibbler CC, Seaton S, Barnes RA. Management and outcome of bloodstream
infections due to Candida species in England and Wales. J Hosp Infect 2003;
54: 18–24.
7) D.  A.  Enoch,  H.  A.  Ludlam  and  N.  M.  Brown.  Invasive  fungal  infections:  a
review of epidemiology and management options. Journal Of Medical
Microbiology 2006, 55: 809–18
8) Bodey JP. Candidiasis in cancer patients. Am J Med 1984; 77:13-19.
9) Dummer JS, Hardy A, Ho M. Early infections in kidney, heart and liver
transplant recipients on cyclosporin. Transplantation 1983; 36(3):259-67.
10) Park K: Epidemiology of Chronic non-communicable disease and conditions.
In  Park’s  Textbook  of  Preventive  and  Social  Medicine.  19th edition.
Banarasidas Bhanot Publishers. Jabalpur, India 2007.
11) Ursula Flückigera, Oscar Marchettib, Jacques Billec, Philippe Eggimannd,
Stefan Zimmerlie. Treatment options of invasive fungal infections in adults.
Swiss Med Wkly 2006 ; 136 : 447 – 63
12) Wey  SB,  Mori  M,  Pfaller  MA,  Woolson  RF,  Wenzel  RP.  Hospital-  acquired
candidemia: the attributable mortality and excess length of stay. Arch Intern
Med 1988; 148: 2642–5.
13) Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality.
CID  1995; 20: 1531–4.
14) Rentz AM, Halpern MT, Bowden RA. The impact of candidemia on length of
hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:
781–8.
15) Gudlaugsson  O,  Gillespie  S,  Lee  K,  Vande  BJ,  Hu  J,  Messer  S.  Attributable
mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:
1172–7.
16) Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic
review of the literature. Clin Infect Dis 2001; 32: 358–66.
17) Michael  A.  Pfaller,  Peter  G.  Pappas,  and  John  R.  Wingard. Invasive fungal
pathogens: Current Epidemiological Trends. Clin Infect Dis; 43(3):14 .
18) Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct
cost and incidence of systemic fungal infections. Value Health 2002; 5:26–34.
19) Zaoutis  TE,  Argon  J,  Chu  J,  Berlin  JA,  Walsh  TJ,  Feudtner  C.et al. The
epidemiology and attributable outcomes of Candidemia in adults and children
hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;
41:1232–9.
20) Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections
due to Candida species and in vitro susceptibilities of isolates collected from
1998 to 2000 in a population-based active surveillance program. JCM 2004;
42:1519–27.
21) Patterson TF, Kirkpatrick WR, White M. Invasive aspergillosis: disease
spectrum, treatment practices, and outcomes. Aspergillus Study Group.
Medicine (Baltimore) 2000; 79:250–60.
22) Reingold AL, Lu XD, Plikaytis BD, Ajello L. Systemic mycoses in the United
States, 1980–1982. J Med Vet Mycol 1986; 24:433–6.
23) Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The
epidemiological features of invasive mycotic infections in the San Francisco
Bay area, 1992–1993: results of population-based laboratory active
surveillance. Clin Infect Dis 1998; 27:1138–47.
24) Marcio Nucci and Elias Anaissie et al. Review of organisms causing infections
in Immunocompromised Patients. ASM.  2007;20(4):695–704
25) Anaissie and bodey G.P. Fungal infection in patients with cancer
Pharmacotherapy;10: 1645-95
26) Carpenter F.M, Fiehn T.E and Armstrong D. Fungemia in the
immunocompromised host. AJM; 71: 363-70
27) Chuck  SL  and  Sandle  MA.  Infection  with Cryptococcus neoformans in
acquired immune deficiency syndrome. New England Journal of Medicine;
321: 794-9
28) Dupont B, Graybill JR, Armstrong B, Laroche R, Touze JE and Wheat LJ.
Fungal infections in AIDS patients. Journal of Medical Mycology; 30: 19-28
29) David Greenwood, Richard Slack, John Peutherer, Mike Barer. Medical
microbiology. Fungi. 17 th edition Elsevier. ISBN 9780443102103: 596-620
30) Emmons CW. Binford CH, Utz JP and Kwon Chung KJ. Medical mycology 3rd
edition 282-3
31) Whittakar R.H. New concepts of kingdom of organisms, science. 163: 150-60
32) Reger L Harvey, Joseph P Myers. Nosocomial fungemia in a large community
hospital. Archives of Internal Medicine;147: 2117-20
33) Resis E, Morrison CJ. Non culture methods for diagnosis of disseminated
candidiasis. Clinical microbiology reviews: 311-23
34) Esselbacher, Brawnwald, Wilson, Martin, Farici, Kasper. Harrison’s principle
of internal medicine. 18th edition
35) Bodo Wanke, Márcia dos Santos Lazéra, Marcio Nucci. Fungal Infections in
the Immunocompromised Host. Mem Inst Oswaldo Cruz, Rio de Janeiro, 2000;
95: 153-8
36) Stefanini M, Allegra S. Pulmonary mucormycosis in acute histiocytic
leukemia. N Engl J Med1957; 256: 1026-30
37) Hurley R. Acute disseminated (septicaemic) moniliasis in adults and children.
Postgrad Med J 1964;40: 644-53. Hurley R. Acute disseminated (septicaemic)
moniliasis in adults and children. Postgrad Med J 1964;40: 644-53.
38) Bodey GP, Anaissie EJ. Opportunistic fungal infections: a major problem in
immunocompromised patients. In RG Richardson, Opportunistic Fungal
Infections: Focus on Fluconazole, International Congress and Symposium
Series, Royal Society of Medicine Services Limited, London. 1989: 1-16.
39) Ben De Pauw, Thomas J. Walsh, J. Peter Donnelly, David A. Stevens, John E.
Edwards,  Thierry  Calandra,  Peter  G.  Pappas,  Johan  Maertens,  Olivier
Lortholary, Carol A. Kauffman, David W. Denning, Thomas F. Patterson,
Georg Maschmeyer, Jacques Bille, William E. Dismukes, Raoul Herbrecht,
William W. Hope, Christopher C. Kibbler, Bart Jan Kullberg, Kieren A. Marr,
Patricia Munoz, Frank C. Odds, John R. Perfect, Angela Restrepo, Markus
Ruhnke, Brahm H. Segal, Jack D. Sobel, Tania C. Sorrell, Claudio Viscoli,
John R. Wingard, Theoklis Zaoutis, and John E. Bennettb.Revised Definitions
of Invasive Fungal Disease from the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813–21
40) S. Ascioglu, J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W.
Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J.
Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A.
Stevens, and T. J. Walsh,et al.,   Defining Opportunistic Invasive Fungal
Infections in Immunocompromised Patients with Cancer and Hematopoietic
Stem Cell Transplants: An International Consensus Clin Infect  Dis 2002;
34:7–14
41) Malcolm  D  Richardson,  Brian  L  Jones. Guidelines in Systemic Fungal
Infections Third Edition. Clinical and Laboratory Diagnosis  Chapter  1
Definitions of fungal infections 2-6
42) Jagdish Chander, Text book of Medical Microbiology, third edition ISBN 81-
8803978-0. 57-63.
43) Vincent  JL,  Bihari  DJ,  Suter  PM,  Bruining  HA,  White  J,  Nicolas-  Chanoin
MH, et al. The prevalence of nosocomial infection in intensive care units in
Europe. Results of the European Prevalence of Infection in Intensive Care
(EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:
639–44.
44) Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB.
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases
from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:
309–17.
45) Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E.,
Johnson, E. M., Perry, J. D., Sullivan, D. J. & Wilson, J. A. Management and
outcome of bloodstream infections due to Candida species in England and
Wales. J Hosp Infect 2003;54:18–24.
46) Elizabeth S. Dodds Ashley, Pharm D. Fungal infections in the intensive care
unit.
47)  Denning, D. W. Echinocandin antifungal drugs. Lancet 2003;362: 1142–51.
48) Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N. &
Wenzel, R. P. Nosocomial bloodstream infections in United States hospitals: a
three-year analysis. Clin Infect Dis 1999;29:239–44.
49) Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A. & Gaynes, R. P., and
the National Nosocomial Infections Surveillance System Hospitals. Secular
trend of hospital-acquired candidemia among intensive care unit patients in the
United States during 1989–1999. Clin Infect Dis 2002;35: 627–30.
50) Eggimann, P., Garbino, J. & Pittet, D. Epidemiology of Candida species
infections in critically ill non-immunosuppressed patients. Lancet Infect Dis
2003; 3:685–702.
51) Ellis D. Clinical Mycology. The Human Opportunistic Mycoses, Pfizer Inc.
(Pub.), New York,1994: 166.
52) Dupont B, Graybill JR, Armstrong D, Laroche R, Touzé JE, Wheat LJ. Fungal
infections in AIDS patients. J Med Vet Mycol 1992;30(1): 19-28
53) Kappe R, Levitz S, Harrison TS, Ruhnke M, Ampel NM, Just-Nübling G.
Recent advances in cryptococcosis, candidiasis and coccidioidomycosis
complicating HIV infection. Med Mycol 1998;36 (1): 207-15.
54) Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R.,
Powderly,  W.  G.,  Sobel,  J.  D.  &  Dismukes,  W.  E.,  for  the  Mycoses  Study
Group Cryptococcal Subproject. Practice guidelines for the management of
cryptococcal disease. Clin Infect Dis 2000;30:710–8.
55) Denning, D. W. Invasive aspergillosis. Clin Infect Dis 1998 ;26:781–803.
56) Hagerty, J. A., Ortiz, J., Reich, D. & Manzarbeitia, C. (2003). Fungal
infections in solid organ transplant patients. Surg Infect (Larchmont) 4, 263–
271.
57) Morgan  J,  Wannemuehler  KA,  Marr  KA. Incidence of invasive aspergillosis
following hematopoietic stem cell and solid organ transplantation: interim
results  of  a  prospective  multicenter  surveillance  program. Med Mycol 2005;
43(1):49-58
58) Marcio Nucci and Elias Anaissie . Fusarium Infections in
Immunocompromised Patients. ASM.  2007;20(4):695–704
59) Nelson,  P.  E.,  M.  C.  Dignani,  and  E.  J.  Anaissie.  1994.  Taxonomy,  biology,
and clinical aspects of Fusarium species. Clin. Microbiol. Rev. 7:479–504.
60) Nucci, M., and E. Anaissie. Cutaneous infection by Fusarium species in
healthy and immunocompromised hosts: implications for diagnosis and
management. Clin. Infect. Dis.2002; 35:909–20.
61) Ninet, B., I. Jan, O. Bontems, B. Lechenne, O. Jousson, D. Lew, J. Schrenzel,
R. G. Panizzon, and M. Monod. Molecular identification of Fusarium species
in onychomycoses. Dermatology 2005;210:21–25.
62)  Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in
hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38:1237–
42.
63) Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84
patients with hematologic malignancies and Fusarium infection
64) Husain, S., Alexander, B. D., Munoz, P. & 12 other authors (2003).
Opportunistic mycelial fungal infections in organ transplant recipients:
emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 37,
221–229.
65) Rippon JW 1988. Medical Mycology. The Pathogenic Fungi and the
Pathogenic Actinomycetes, 3rd ed., WB Saunders, Philadelphia, 797.
66) Kwon-Chung KJ, Bennett JE, Lea & Febiger. Medical Mycology
Philadelphia,1992: 866.
67) Malcolm  D  Richardson,  Brian  L  Jones. Guidelines in Systemic Fungal
Infections Third Edition. Clinical and Laboratory Diagnosis  Chapter 6 Fungal
species most commonly recovered from clinical specimens 17-8
68) Malcolm  D  Richardson,  Brian  L  Jones.  Guidelines  in  Systemic  Fungal
Infections Third Edition. Clinical and Laboratory Diagnosis  Chapter  7
Criteria for the diagnosis of systemic fungal infections: clinical features and
laboratory parameters contributing to a definitive diagnosis 19-21
69) Caillot, D., Casasnovas, O., Bernard, A. Improved management of invasive
pulmonary aspergillosis in neutropenic patients using early thoracic computed
tomographic scan and surgery. J Clin Oncol 1997;15: 139–47.
70) Gregory P.Demuri/ Ellen R.Wald: Mandells, Douglas and Bennet’s principles
and practice of infectious disease, 7th edition, Churchill Livingston Elsivier
ISBN 9780443068393: 1039-49.
71) Deanna A Sutton. Specimen collection, transport and processing: Mycology.
Patrick R.Murray manual of clinical microbiology 9th edition. 1728-36
72) William G Merzi, David fay. Susceptibility testing of filamentous fungi to
amphotericin B by a rapid radiometric method. JCM;54-6
73) Szekely  A,  Johnson  E,  Warnock  D.  Comparison  of  E-  test  and  broth
microdilution dilution methods for antifungal drug susceptibility testing of
moulds.JCM; 37: 1480-3.
74) Espinell – ingroff, Pfaller et al. Multicenter evaluation of a new disk agar
diffusion method and sensititer yeast one colorimetric antifungal susceptibility
testing of  filamentous fungi
75) Ellis DH et al. Evaluation of the sensititre yeast one microtitre panel, E test and
Neosensitab disk methods for antifungal susceptibility tests against 4 reference
yeast. IUMS; 3(24)
76) Malcolm  D  Richardson,  Brian  L  Jones. Guidelines in Systemic Fungal
Infections Third Edition. Antifungal Drugs Chapter 9-17
77) Malcolm  D  Richardson,  Brian  L  Jones. Guidelines in Systemic Fungal
Infections Third Edition. Antifungal Drugs Chapter 19
78) Jack.D.Sobel, Jose A.Vazquez. Contemporary diagnosis and management of
fungal infections. Third edition.pg 18-53. Handbooks in Health Care
79) Bibi  folder  31  now  in  48  Vijaya  R.Bhatt,  George  M.Viola  and  Alessandra
Ferrajoti et al. Invasive fungal infections in acute leukemia. Ther Adv Hematol
2011; 2(4): 231-47
80) Malcolm  D  Richardson,  Brian  L  Jones. Guidelines in Systemic Fungal
Infections Third Edition. Antifungal Drugs Chapter 18
81) Malcolm  D  Richardson,  Brian  L  Jones. Guidelines in Systemic Fungal
Infections Third Edition. Antifungal Drugs Chapter 20
82) Elmer V Koneman, Gary W Procop, Paul C. Schreckenberger, Koneman’s
color atlas and textbook of diagnostic Microbiology,6th
edition:Mycology,.Lippincott William and Wilkins ISBN 0-7817-3014-7.
1160-3
83) Arunloke chakrabarthy, M.R.Shivprakash, workshop manual on diagnostic
mycology, Microcon 2009.
84) Reference method for Broth Dilution Antifungal susceptibility testing of
Filamentous Fungi; Approved Standard (M – 38 A). CLSI
85) KL Therese,  R Bagyalakshmi,  HN Madhavan, P Deepa In-vitro susceptibility
testing by agar dilution method to determine the minimum inhibitory
concentrations of amphotericin B, fluconazole and ketoconazole against ocular
fungal isolates.
86) A.Espinell  –Ingroff,  BArthington  –Skaggs  et  al  ,Multicenter  evaluation  of  a
new disk agar diffusion method for susceptibility testing of filamentous fungi
with voriconazole, Posoconazole, Itraconazole, Amphotericin B and
caspofungin.JCM 2007: 1811-20.
87) Shawn  A.  Messer,  Daniel  J  Diekema  et  al,Evalation  of  disk  diffusion  and  E
tests compared to Broth microdilution for antifungal susceptibility testing of
Posaconazole against clinical isolates of filamentous fungi,JCM.2007. 1322-4.
88) Rex J, Pfaller M, Walsh T et al.: Antifungal susceptibility testing: practical
aspects and current challenges. Clin. Microbiol. 2001(14), 643-58.
89) Pfaller M, Messer SA, Mills K, Bolmstrom A: In vitro susceptibility testing of
filamentous fungi: comparison of Etest and reference microdilution methods
for determining itraconazole MICs. JCM. 2000 ((38) 3359-61
90) Szekely  A,  Johnson  E,  Warnock  D:  Comparison  of  E-test  and  broth
microdilution methods for antifungal drug susceptibility testing of moulds.
JCM. 1999 (37), 1480-3
91) Shadomy, S., and A. Espinel-Ingroff. 1980. Susceptibility testing with
antifungal drugs, p. 647-653. In E. H. Lennette, A. Balows, W. J. Hausler, Jr.,
and J. P. Truant (ed.), Manual of clinical microbiology, 3ed,ASM Washington,
92) Anna  Wald,Wendy Leisenring,Jo-Anne  van  Burik  and  Raleigh  A.  Bowden et
al. Epidemiology of Aspergillus Infections in a large cohort of patients
undergoing Bone marrow transplantation. Journal Of Infectious Diseases
1997;175:1459-66
93) Kieren A.Marr, Rachel A.Carter, Fulvio Crippa, Anna Wald and Lawrence
Corey et al., Epidemiology and outcome of mould infections in Hematopoietic
stem cell transplant recipients. Clin Infect Dis 2002;34:909-17
94) Dimitrios  P  Kontoyiannis,  Kieren  A  Marr,  Benjamin  J  Park,  Barbara  D
Alexander, Elias J Anaissie, Thomas J Walsh, James Ito, David R Andes, John
W Baddley, Janice M Brown, Lisa M Brumble, Alison G Freifeld, Susan
Hadley, Loreen A Herwaldt, Carol A Kauffman, Katherine Knapp, G Marshall
Lyon,  Vicki  A Morrison,  Genovefa  Papanicolaou,  Thomas  F  Patterson,  Trish
M Peri, Mindy G Schuster, Randall Walker, Kathleen A Wannemuehler, John
R Wingard,  Tom M Chiller And Peter G Pappas.  Prospective surveillance for
invasive fungal infections in Hematopoietic stem cell transplant recipients,
2001-2006: overview of the Transplant- Associated Infection Surveillance
Network(TRANSNET) database. bnv 2010;50: 1091-100
95) L.Pagano, M.Caira, A.Nosari, M.T Van Lint, A.Candoni, M.Offidani, T.Aloisi,
G.Irrera, A.Bonini,M.Picardi, C.Caramatti, R.Invernizzi, D.Mattei, L.Malillo,
C.de Waure,G.Reddiconto, L.Fianchi, C.G.Valentini, C.Girmenia,G.Leone and
F.Aversa. Fungal infections in recipients of  Hematopoietic stem cell
transplants: Resuls of the SEIFEM BB-2004 study – Sorveglianza
epidemiological infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis
2007;45:1161-70
96) Siok-Ying  Lee,  Chay-Leng  Yeo,  Winnie  H Lee,  Andrea  L  Kwa,  Liang  –Piu-
Koh, Li-Yang Hsu. Prevalence of invasive fungal disease in hematological
patients at a tertiary university hospital in Singapore. Bmc Research Notes
2011;4:42
97) Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes
mellitus and complications. Part 1. Diagnosis and classification of diabetes
mellitus provisional report of a WHO consultation. Diabet Med 1998;
15(7):539-53.
98) Aly FZ, Blackwell CC, Mackenzie DAC, Weir DM, Clarke BF. Factors
influencing oral carriage of yeasts among individuals with diabetes mellitus.
Epidemiol Infect 1992; 109(3):507-18.
99) Aly FZ, Blackwell  CC, MacKenzie DA, Weir DM, Elton RA, Cumming CG,
et al. Chronic atrophic oral candidiasis among patients with diabetes mellitus-
role of secretor status. Epidemiol Infect 1991; 14(1):48-53.
100) Bouter KP, Diepersloot RJ, Van Romunde LK, Uitslager R, Masurel N,
Hoekstra JB, et al. Effect of epidemic influenza on ketoacidosis, pneumonia
and death in diabetes mellitus: A hospital register survey of 1976-9 in the
Netherlands. Diabetes Res Clin Pract 1991; 12(12):61-8.
101) F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist, and G. Dulai. Hepatitis C virus
antibody status and survival after renal transplantation: meta-analysis of
observational studies. American Journal Of Transplantation 2005;5(6):
1452– 61.
102) Marr  KA,  Siedel  K,  White  TC,  Bowden  RA.  Candidemia  in  allogenic  blood
and marrow transplant recepients: evolution  of risk factors after  the adoption
of prophylactic fluconazole. J Infect Dis. 2000;181: 309-16
103) Carol A. Kaufmann. The changing landscape of invasive fungal infections:
Epidemiology. Diagnosis and pharmacologic options. Clin Infect Dis
2006;43(1):2
104) Johan Maertens. Evaluating prophylaxis of invasive fungal infections in
patients with haematologic malignancies. European Journal Of Haematology
2007;78: 275-82.
105) B  George,  V  Mathews,  A  Srivastava  and  M  Chandy.  Infections  among
allogenic bone marrow transplant recipients in India. Bone Marrow
Transplantation 2004; 33:311-5.
106) L.Pagano, M.Caira, A.Nosari, M.T Van Lint, A.Candoni, M.Offidani, T.Aloisi,
G.Irrera, A.Bonini,M.Picardi, C.Caramatti, R.Invernizzi, D.Mattei, L.Malillo,
C.de Waure,G.Reddiconto, L.Fianchi, C.G.Valentini, C.Girmenia,G.Leone and
F.Aversa. Fungal infections in recipients of  Hematopoietic stem cell
transplants: Resuls of the SEIFEM BB-2004 study – Sorveglianza
epidemiological infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis
2007;45:1161-70
107) Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C et al.
European confederation of Medical Mycology (ECMM) prospective survey of
candidaemia: report from one Italian region. J Hosp Infect;51:297-304.
108) Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trends of
hospital-acquired candidemia among chemotherapeutic  patients in the United
States during 1989-1999. CID 2002;35:627-630.
109)  Patrício Richet, Iris Nora Tiraboschi, Luiz Carlos Severo. Species Distribution
and Antifungal Susceptibility Profile of Candida spp. Bloodstream
Isolates CMI 4(3): 23-6
110) Bodey GP, Anaissie EJ. Opportunistic fungal infections: a major problem in
immunocompromised patients. In RG Richardson, Opportunistic Fungal
Infections: Focus on Fluconazole, International Congress and Symposium
Series, Royal Society of Medicine Services Limited, London. 1989: 1-16.
111) Hurley R. Acute disseminated (septicaemic) moniliasis in adults and children.
Postgrad Med J 1964;40: 644-53.
112) Zarei-Mahmoudabadi A, Zarrin M, Ghanatir F, Vazirianzadeh B. Candiduria in
hospitalized patients in teaching hospitals of AhvazIJM; 4(4): 198-203
113) Iatta R, Caggiano G, Cuna T, Montagna MT. Antifungal susceptibility testing
of a 10-year collection of Candida spp. isolated from patients with candidemia.
J Chemother. ;23(2):92-6.
114) Francesco Barchiesia , Anna Maria Tortorano, Luigi Falconi Di
Francesco,Massimo Cogliati, Giorgio Scalisea and Maria Anna Viviani. In-
vitro activity of five antifungal agents against uncommon clinical isolates
ofCandida spp.JAC; 43(2): 295-9
115) Nidhi Goel, Prabhat K Ranjan, Ritu Aggarwal, Uma Chaudhary, and Nanda
Sanjeev . Emergence of Nonalbicans Candida in Neonatal Septicemia and
Antifungal Susceptibility: Experience from a Tertiary Care Center. J  Lab
Physicians; 1(2): 53–5.
116) Lennox K. Archibald , Marion J. Tuohy, Deborah A. Wilson, Okey
Nwanyanwu, Peter N. Kazembe, Somsit Tansuphasawadikul, Boonchuay
Eampokalap, Achara Chaovavanich, L.Barth Reller, William R. Jarvis, Gerri S.
Hall, and Gary W. Procop Antifungal Susceptibilities of Cryptococcus
neoformans.CDC. ;4(1):143-45
117) KL Therese,  R Bagyalakshmi,  HN Madhavan, P Deepa In-vitro susceptibility
testing by agar dilution method to determine the minimum inhibitory
concentrations of amphotericin B, fluconazole and ketoconazole against ocular
fungal isolates.
118) Serrano MC, M.Ramirez, D et al. A comparative study of disk diffusion
method with broth dilution method and E test methods for voriconazole
susceptibility testing of Aspergillus spp.JAC; 53: 739-42
119) Denning, D. W. Echinocandin antifungal drugs.Lancet 2003;362:1142–51.
120) Georg Maschmeyer. The changing epidemiology of invasive fungal infections:
new threats. IJAA 2006;27:3-6
121) McNeil MM,Nash SL,Hajjeh RA. Trends in mortality due to invasive mycotic
diseases in United States. 1980-1997. Clin Infect Dis 2001;33:641-7
122) Jantunen E, Salonen J, Juvonen E, et al. Invasive fungal infection in
autologous stem cell transplantation: a nation-wide study of 1188 transplanted
patients. Eur J Hae Matol2004; 73:174-8
123) Fran fisher, Norma B.Cook. Fundamentals of diagnostic Mycology,
1998.(Elsevier).
124) Reference method for Broth Dilution Antifungal susceptibility testing of  yeast
and yeast like fungi; Approved Standard (M – 27 A). CLSI
125) Reference method for disc diffusion Antifungal susceptibility testing of yeast
and yeast like fungi  ; Approved Standard (M – 44A). CLSI
126) A.Espinel-Ingroff etal .2006.Comparison of three commercial assays and a
modified disk diffusion assay with two broth microdilution reference assays for
testing zygomycetes, Aspergillus spp, Candida spp and Cryptococcus
neoformans with posaconazole and Amphotericin B.JCM .44:3616-22.
ABBREVIATIONS
AIDS Acquired immune deficiency syndrome
AST Antifungal susceptibility test
BSI Blood stream infections
CLSI
CMV
Clinical and laboratory standards  institute
Cytomegalovirus
CT Chemotherapy
CXR Chest X ray
DD Disc diffusion
DM Diabetes mellitus
DMSO Dimethyl sulfoxide
E TEST Epsilometer test
ELISA Enzyme Linked Immunosorbent Assay
GMS Gomori Methenamine Silver
H&E Haematoxylin and eosin
HCV Hepatitis C virus
HPE Histopathological examination
HIV
HSV
Human immunodeficiency virus
Herpes simplex virus
IFI Invasive fungal infection
KOH Potassium hydroxide mount
LAT Latex agglutination test
M Minor error
M Major error
VM Very Major error
MHA Mueller Hinton Agar
MIC Minimum Inhibitory Concentration
MOPS 3N-Morpholino Propane Sulphonic Acid
MRI
NCA
Magnetic resonance imaging
Non Candida albicans
PAS
PCR
Periodic Acid Schiff
Polymerase chain reaction
PDA Potato Dextrose agar
PNA FISH peptide nucleic acid fluorescence in situ
hybridization
RPMI Rosewall Park Memorial Institute
RT Renal transplantation
R Resistant
S Susceptible
SDD Susceptible Dose Dependent
APPENDIX I
A. STAINS AND REAGENTS
1) 10% POTASSIUM HYDROXIDE SOLUTION:
Potassium hydroxide   10 gm
Glycerol   10 ml
Distilled water    80 ml .
2) LACTOPHENOL COTTON BLUE STAIN
Lactic acid 20 ml
Phenol 20 ml
Cotton blue (dye) 0.5 g
Glycerol 40 ml
Distilled water 20 ml
3) GRAM STAINING
Methyl violet (2%)             l0g Methyl violet in l00ml absolute alcohol in 1litre of
                                            distilled water (primary stain)
Grams Iodine                      l0g Iodine in 20g KI (fixative)
Acetone                               Decolourising agent
Carbol fuchsin                     1% Secondary stain
4) INDIA INK PREPARATION- NEGATIVE STAINING:
India ink                                            150ml
Merthiolate (1:1000)                             3ml
Tween 80(1:10000)                            0.1ml
5) NIGROSIN STAIN:
Nigrosin granules                             10gm
Formalin (10%)                                100ml
6)CALCOFLUOR WHITE STAIN:
CFW M2R                                         100mg
Evans blue                                           50mg
Distilled water                                   100ml
B. MEDIA USED
1)SABOURAUD DEXTOSE AGAR WITH ANTIBIOTICS:
Ingredient                      gm/ltr
Peptone             10 gms
Dextrose             40 gms
Agar             20 gms
Distilled water            1000 ml
Gentamicin             20 mg
Final pH was adjusted to 5.6.
The above ingredients were reconstituted in one litre of distilled water. Dissolve
the powder in distilled water by boiling. Gentamicin is added to the boiling medium.
The medium was then removed from heating,  mixed well  and then dispersed in tubes
and autoclaved at 1210 C for 15 minutes and the final pH was adjusted to 5.6. The tubes
were cooled in slanted position and later the slants were stored in refrigerator.
2) YEAST NITROGEN BASE AGAR MEDIUM(DEHYDRATED NEDIA,
(Himedia, MUMBAI)
INGREDIENTS GRAMS/L INGREDIENTS GRAMS/L
Ammonium sulphate 5.00 Thiamine
hydrochloride
0.004
L-Histidine
hydrochloride
0.01 Boric acid 0.0005
DL-Methionine 0.02 Copper sulphate 0.00004
DL-Tryptophan 0.02 Potassium iodide 0.0001
Biotin 0.000002 Ferric chloride 0.0002
Calcium
pantothenate
0.00004 Manganese sulphate 0.0004
Folic acid 0.000002 Sodium molybdate 0.0002
Inositol 0.02 Zinc sulphate 0.0004
Niacin 0.0004 Monopotassium
phosphate
1.00
Para amino benzoic
acid
0.0002 Magnesium sulphate 0.50
Pyridoxine
hydrochloride
0.0004 Sodium chloride 0.10
Riboflavin 0.0002 Calcium chloride 0.10
Dissolve 6.7 gms of the media in 100 ml of distilled water. Sterilise by
filteration and store at 40C.
3) MUELLER HINTON AGAR:
Beef infusion : 300 ml
Casein hydrosylate : 17.5 gm
Starch : 1.5 gm
Agar : 10 gm
Distilled Water : 1000 ml
pH : 7.4
Sterilize by autoclaving at 1210 C for 20 minutes.
4) RPMI 1640(ROSEWALL PARK MEMORIAL INSTITUTE) MEDIA:
RPMI medium : 10.4 gm
MOPS buffer : 34.43 gm
Dissolve powered medium in 900 ml distilled water. Add MOPS to a final
concentration of 0.165 mol/L and stir until dissolved. While stirring, adjust the pH to
7.0 at 250 C. Add additional water to bring medium to a final volume of 1000 ml. Filter
sterilize and store at 40 C.
5) POTATO DEXTROSE AGAR:
Ingredient                      gm/ltr
Potato 200 gms
Dextrose  20 gms
Agar 20 gms
Water  1 Litre
Boil 200 g of potatoes in 1 litre of water for 60 minutes. Squeeze as much as pulp as
possible through a fine sieve. Add agar and boil till it dissolves. Add dextrose and make
upto 1 litre. Dispense in required amounts taking care to keep the solids in suspension.
Autoclave at 1150 C for 30 minutes. Cool to 500 C and pour into petridishes.
6)CAFFEIC ACID FERRIC CITRATE MEDIUM
Ingredient                                                     gm/ltr
Yeast extract                                                   2
Dextrose                                                          5
Ammonium sulphate                                       5
Dipotassium phosphate                                    5
Magnesium sulphate                                        0.7
Caffeic acid                                                      0.18
Ferric citrate                                                     0.02
Agar                                                                 20
    pH 6.5+ 0.2
Suspend 33.7 grams in 1 litre of distilled water. Heat until the solution boils to dissolve
the contents completely. Sterilize by autoclaving at 1210C for 15 minutes. Cool to
550C, add chloramphenicol 50µg/ml and dispense in plates/ tubes
7)CHROMAGAR CANDIDA MEDIUM:
Ingredient                                                          gm/ltr
Peptone                                                               15gms
Yeast extract                                                          4gms
Dipotassium hydrogen phosphate                          1gm
Chromogenic Mixture                                             7.22gms
Chloramphenicol                                                    0.50gms
Agar                                                                       15gms
pH   6.3+ 0.2 at 250C
42.72 gms of media suspended in 1000ml distilled water and heated to boiling for the
medium to dissolve completely. Not to be autoclaved. Cool to 500C and dispense in
sterile petriplates.
8)BRAIN HEART INFUSION AGAR(BHIA):
Brain Heart Infusion                      37 gms
Glucose                                          20gms
L-Cysteine hydrochloride                1 gm
Agar                                                20gms
Distilled water                               900ml
Gentamicin : 20 mg
Final pH was adjusted to 5.6.
Ingredients are dissolved  by boiling and dispensed in screw capped  tubes and
autoclaved at 1210C for 15 minutes.
9)BIPHASIC MEDIUM:
BHIA plus broth
BHIA is sterilised first and bottles are kept at slanting position, then BHI broth added
aseptically to cover 40% of agar in standing position.
10) Blood agar (5% sheep blood agar)
                     Peptone                    -          l0g
                     Nacl                          -          5g
                     Distilled water           -         1 Ltr
                     Agar                          -         10g
Dissolve  ingredients  in  distilled  water  by  boiling,  and  add  5%  sheep blood
(sterile) at 55°C adjust pH to 7.4.
C. MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION
1)CHRISTENSEN’S UREASE TEST MEDIUM
Peptone                                                          1g
Sodium chloride                                            5g
Dipotassium hydrogen phosphate                 2g
Phenol red                                                    6ml
Agar                                                             20g
Distilled water                                              1 ltr
10% sterile solution of glucose                   l0ml
Sterile 20% urea solution                           l00ml
Sterilize the glucose and urea solutions by filtration. Prepare the basal medium without
glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving in a flask at 121°C
for 30min. Cool to about 50°C, add the glucose & urea, and tube the medium as slopes.
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APPENDIX III- PROFORMA
S.no:                                                                          IP no:
Name :                                                                      Ward:
Age:                                                                           Sex:
Occupation:                                                               Address:
PRESENTING COMPLAINTS:                                  Duration
H/O Diabetes mellitus
H/O Cancer
H/O immunosuppressive therapy
H/O Uremia/Chronic kidney disease
H/O Prior transplant surgery
H/O Prior antibiotic therapy
Previous  H/O IFI
H/O dialysis
H/O iron therapy
PHYSICAL EXAMINATION:
BIOLOGICAL PARAMETERS:
Blood sugar (fasting and post prandial)
S.urea:
S.creatinine:
OTHER INVESTIGATIONS:
Complete hemogram:
Total WBC count
Differential count:
ESR:
Renal function test:
Liver function test:
CD4 count:
HCV/CMV/HSV:
X ray chest:
CT Chest:
MRI:
Histopathological examination:
MICROBIOLOGICAL EXAMINATION:
Direct examination: KOH & India ink
Gram stain
Culture :
          Antimicrobial sensitivity pattern:
1. Disk diffusion:
2. MIC:
             By Broth dilution
             By Agar dilution
             By E test
APPENDIX IV- CONSENT FORM
STUDY TITLE :
A STUDY ON INVASIVE FUNGAL INFECTIONS AMONG
IMMUNOCOMPROMISED PATIENTS IN A TERTIARY CARE
HOSPITAL
Name:                                                                    Date:
Age/Sex:                                                                IP.no:
           I conform that I understand the purpose of the above study and I
have the opportunity to ask questions. All my questions and doubts have
been answered to my satisfaction. I understand that my participation in this
study is voluntary and I am free to withdraw at any time without giving
any reason. I understand that the investigator, regulatory authorities and
ethical committees will not need my permission, to look at my health
records both in respect to current study and any further research that
conducted in relation to it. I also give my consent for my investigator to
publish the data in any forum or journal.
           I understand that my  participation in the study will not affect  my
treatment. I have received information sheet regarding the study. I hereby
consent to participate in the study “A STUDY ON INVASIVE FUNGAL
INFECTIONS AMONG IMMUNOCOMPROMISED PATIENTS IN A
TERTIARY CARE HOSPITAL” conducted at the Institute of
Microbiology, Madras Medical college & Rajiv Gandhi Government
General Hospital, Chennai-03
Date:
Place:
                            Signature/ Thumb impression of the patient
S.NO AGE SEX SAMPLE PERIOD OF CONDITION
RENAL
TX
DM CT HIV HCV DIAGNOSIS SYMPTOMS HPE ORGANISM DEATH D AMPHO D ITRA D FIU MIC AMPHO MIC ITRA MIC FLU MIC VORI
E TEST
AMP
Agar dilution
method AMP
AGAR
DIL ITRA
1 60 Male urine 7yrs + + PUO/ UTI fever,dysuria C.tropicalis S S S S S S R S S S
2 72 Male Blood 10yrs + + sepsis fever C.glabrata S S R S S R S S S S
3 30 Male pus 2yrs + brain abscess headache,nausea,vomit + + Asp.terreus R R R S S R R S
4 40 Male Br.wash 3yrs + invasive aspergillosis Fever and chills,hemoptysis,shortness of breath + Asp.flavus S S S S S S S S
5 60 Male Br.wash 10yrs + consolidation breathlessness, cough + Asp.terreus R S R S S R R S
6 43 Male Aspirated FNAC 3yrs + infraorbital granuloma orbital swelling,headache + + Asp.flavus S S S S S S S S
7 34 Male pus 2yrs + + left thigh abscess + + dematatious fungi S S S
8 28 Male BAL 2yrs + + interstitial pneumonia breathlessness, dry cough + Asp.fumigatus S S S S S S S S
9 47 Female Br.wash 6yrs + pneumonia Asp.fumigatus SDD S S S S S S S
10 36 Male Br.wash 4yrs + pneumonia Asp.fumigatus R S S S S S S S
11 54 Male Br.wash 5yrs + Rt UL mass Asp.fumigatus S S S S S S S S
12 22 Female urine 4yrs + sepsis C.parapsilosis S S S S S S S S S S
13 17 Female urine 2yrs + PUO C.tropicalis S S S S S S R S S S
14 45 Female urine 5yrs + T2DM/sepsis C.tropicalis S S S S S S R S S S
15 45 Male Br.wash 6yrs + pneumonia breathlessness, dry cough Asp.fumigatus S S S S S S S S
16 29 Female urine 6months + UTI DIALYSIS NG
17 39 Male BAL 4yrs + invasive aspergillosis hemoptysis,shortness of breath Asp.fumigatus S S S S S S S S
18 28 Female IJV catheter tip 1 month + PUO C.albicans S S S S S S S S S S
19 42 Female Br.wash 3yrs + + pneumonia breathlessness, dry cough Asp.fumigatus S R S S S S S S
20 57 Male Br.wash 7yrs + pneumonia breathlessness,dry cough Asp.fumigatus R R S R S S S S
21 47 Male Br.wash 7yrs + pneumonia breathlessness,dry cough Asp.fumigatus S SDD S S S S S S
22 47 Male Br.wash 5yrs + CML & pneumonia breathlessness,dry cough Asp.flavus S S S S S S S S
23 42 Male Blood 2yrs/ 1year(DM) + + + sepsis Acute jaundice,Graft Failure, CMV NG
24 30 Male orbital FNAC 5yrs + + Rhinocerebral mucormycosis orbital swelling, + + Rhizopus oryzae S S S S S S S S
25 42 Female urine 10yrs + UTI C.albicans S S S S S S S S S S
26 30 Male urine 6 months + + UTI NG
27 23 Male urine 6 months + + UTI NG
28 26 Male urine 1yr + + UTI Abd.pain, NG
29 42 Male urine,drain,catheter 1 month + + NG
30 44 Male urine,drain,catheter 1 month + + + NG
31 40 Male urine,drain,catheter 1 month + HSV NG
32 58 Male FNAC debriment 8yrs + Rt Orbital cellulitis & fungal sinusitis + + Absidia corymbifera S S S S S S S S
33 20 Male urine,drain,catheter 1 month + NG
34 27 Male urine 4yrs + + UTI Graft dysfunction, HSV NG
35 14 Male urine,drain,catheter 1 month + NG
36 13 Female urine,drain,catheter 1 month + + NG
37 26 Male pus 4yrs + Left leg abscess NG
38 28 Female urine 2yrs + UTI NG
39 33 Female CSF 3yrs + meningitis HSV NG
40 45 Male BAL 7yrs + interstitial pneumonia + Asp.nidulans S S S S S S S S
41 40 Male urine 2yrs + UTI NEUTROPENIA NG
42 45 Male Brain abscess 5yrs + + + + Rhizopus oryzae + S S S S S S S S
43 35 Female sputum 5yrs + + Exserohilum sp S S S
44 30 Male B.wash 5yrs + invasive aspergillosis hemoptysis,shortness of breath + Asp.fumigatus S S S S S S S S
45 51 Male BAL 7yrs + invasive aspergillosis hemoptysis,shortness of breath + Asp.terreus R S R S S R R S
46 30 Female B.wash 4yrs + consolidation breathlessness Curvaiaria lunaeta SDD S S S S S S S
47 28 Female Urine 3yrs + UTI C.tropicalis S S R S S S R S S S
48 40 Male Urine 2yrs + UTI NG
49 20 Male Urine 1yr + UTI NG
50 42 Male urine,drain tube,catheter 1mon + NEUTROPENIA NG
51 26 Male drain 10days + C.albicans SDD S S S S S S S S S
52 46 Male urine/drain 1 month + NG
53 35 Male urine 2yrs + UTI NG
54 29 Male urine 1mon + UTI NG
55 27 Male urine 3yrs + UTI & graft failure HSV NG
56 25 Male Ascitic fluid 10yrs + + Ascitis Abd pain, abd distention NG
57 45 Male pus 1yr + Genital ulcer HSV NG
58 26 Male Urine 2yrs + UTI NEUTROPENIA NG
59 42 Male Blood 14yrs + + Graft failure NG
60 24 Male Blood 9months + PUO Fever, jaundice, HSV NG
61 60 Female Br.wash 17yrs + Ca oesophagus NG
62 40 Male Ascitic fluid 2yrs + Ca head of pancreas NG
63 60 Male Br.wash 19yrs + Ca oesophagus NG
64 75 Male Br.wash 20yrs + Ca oesophagus NG
65 33 Male pl.fluid 2yrs + Pleural malignancy NG
66 38 Female Gastric lavage 3yrs + Gastric ca C.albicans S S S S S S S S S S
67 68 Male Br.wash 18yrs + Ca lung Asp.flavus SDD R S S S S S S
68 48 Male Br.wash 14yrs + Ca lung & secondaries in neck NG
69 40 Female urine 3yrs + T2DM/UTI NG
70 20 Female Urine 2yrs + T2DM/UTI NG
71 37 Female Urine 3yrs + T2DM/UTI NG
72 38 Female urine 4yrs + T2DM/UTI C.parapsilosis S S S S S S S S S S
73 40 Female urine 2yrs + T2DM/UTI NG
74 46 Female urine 3yrs + T2DM/UTI NG
75 52 Female urine 2yrs + T2DM/UTI NG
76 35 Female urine 2yrs + T2DM/UTI NG
77 35 Female urine 1yr + T2DM/UTI NG
78 55 Male urine 4yrs + T2DM/UTI NG
79 44 Female urine 3yrs + T2DM/UTI C.albicans S S S S S S S S S S
80 45 Female urine 5yrs + T2DM/UTI NG
81 31 Male urine 2yrs + T2DM/UTI NG
MASTER CHART
82 51 Male urine 5yrs + T2DM/UTI NG
83 55 Male urine 4yrs + T2DM/UTI NG
84 45 Male urine 3yrs + T2DM/UTI NG
85 35 Male urine 2yrs + T2DM/UTI NG
86 50 Male urine 5yrs + T2DM/PUO PUO C.albicans S S SDD S S S S S S S
87 55 Male urine 7yrs + T2DM/UTI C.albicans S S S S S S S S S S
88 50 Male urine 5yrs + T2DM/UTI NG
89 23 Male urine 3yrs + T1DM/UTI NG
90 39 Male urine 3yrs + T2DM/UTI NG
91 45 Female urine 6yrs + T2DM/UTI NG
92 18 Male urine 2yrs + T1DM/UTI NG
93 33 Male urine 3yrs + T2DM/UTI NG
94 63 Female urine 12yrs + T2DM/UTI C.albicans R S R S S S S S S S
95 50 Male urine 5yrs + T2DM/UTI NG
96 39 Male pus 3yrs + T2DM & pneumonia Asp.flavus R R S S S S S S
97 68 Male pl.fluid 15yrs + Rt loculated empyema Asp. terreus R S R S S R R S
98 17 Male urine,drain,catheter 1 month + DIALYSIS NG
99 45 Female pus 10yrs + Rt thigh abscess- lateral aspect C.albicans S S S S S S S S S S
100 20 Male sputum 5yrs + AML + Fusarium sp R R R R S R R R
101 50 Male Ascitic fluid 10yrs + + Peritoneal carcinomatation with liver metastasis + Asp.flavus S S S S S S S S
102 39 Female urine 5yrs + UTI fever,dysuria C.albicans S S S S S S S S S S
103 55 Female urine 7yrs + UTI C.glabrata S S R S S R S S S S
104 61 Female urine 12yrs + UTI C.albicans S S S S S S S S S S
105 22 Female urine 4yrs + UTI C.albicans S S SDD S S S S S S S
106 53 Male Br.wash 8yrs + Lt LL consolidation Penicillium sp S S S S S S S S
107 56 Male Br.wash 12yrs + Rt lung mass Penicillium sp S SDD S S S S S S
108 47 Male Br.wash 7yrs + invasive aspergillosis Asp.fumigatus S S S S S S S S
109 36 Male drain 3yrs + ADD C.glabrata S S R S S R S S S S
110 45 Male Br.wash 7yrs + Rt LL consolidation NG
111 42 Male sputum 8yrs + T2DM/fungal ball Asp.fumigatus S S S S S S S S
112 38 Male pus 3yrs + liver abscess NG
113 42 Male Br.wash 5yrs + Ca lung + Penicillium sp S S S S S S S S
114 47 Male pus 9yrs + Ca lung & multiple abscess all over body C.albicans S S S S S S S S S S
115 64 Male Gastric lavage 10yrs + Ca oesophagus C.albicans S S S S S S S S S S
116 61 Male sputum 5yrs + Mediastinal mass Asp.fumigatus S SDD S S S S S S
117 36 Male FNAC debriment 6yrs + Cavernous sinus thrombus facial puffiness,R nasal block + + Rhizopus oryzae + S S S S S S S S
118 23 Female sputum 10yrs + AML& Rt basal consolidation + Asp.fumigatus + R R R R S S S S
119 35 Male urine 5yrs + UTI C.tropicalis S S S S S S R S S R
120 35 Male urine,drain,catheter 1mon + CMV DIALYSIS NG
121 32 Male urine,drain,catheter 1mon + + NG
122 42 Male urine,drain,catheter 1mon + CMV NEUTROPENIA NG
123 25 Female urine 7yrs + + NG
124 27 Male urine,drain,catheter 1mon + CMV DIALYSIS NG
125 22 Male urine 1yr + UTI, CMV DIALYSIS NG
126 24 Female urine 1yr + UTI NEUTROPENIA NG
127 41 Male urine 1yr + UTI NEUTROPENIA NG
128 28 Male urine,drain,catheter 1mon + DIALYSIS NG
129 25 Female urine 1yr + UTI, CMV NEUTROPENIA NG
130 33 Male urine,drain,catheter 1mon + + NG
131 30 Male urine,drain,catheter 1mon + NEUTROPENIA NG
132 27 Female urine 2yrs + UTI CMV NG
133 25 Female urine,drain,catheter 1mon + DIALYSIS NG
134 37 Male urine,drain,catheter 1mon + + NG
135 30 Female drain 3yrs + ADD, CMV NEUTROPENIA NG
136 33 Male urine,drain,catheter 1mon + DIALYSIS NG
137 30 Male urine,drain,catheter 1mon + CMV NG
138 42 Male Blood 7yrs + sepsis C.glabrata S S R S S R S S S S
139 55 Male sputum 15yrs + NHL NG
140 52 Male pl.fluid 5yrs + Ant.mediastinal mass NG
141 32 Male pl.fluid 2yrs + Malignant mesothelioma NG
142 45 Male Ascitic fluid 3yrs + Ca stomach with liver metastasis NG
143 59 Male sputum 9yrs + Ca lung + Asp.fumigatus S S S S S S S S
144 30 Male sputum 5yrs + invasive aspergillosis + Asp.niger S S S S S S S S
145 64 Male Br.wash 8yrs + invasive aspergillosis Asp.fumigatus SDD S S S S S S S
146 65 Male pl.fluid 15yrs + invasive aspergillosis Asp.fumigatus S S S S S S S S
147 46 Male sputum 6yrs + MDS & invasive aspergillosis + Asp.flavus S SDD S S S S S S
148 52 Male sputum 10yrs + MDS & Aspergilloma Asp.fumigatus S S S S S S S S
149 55 Female Br.wash 10yrs + + Ca lung + Asp.flavus S S S S S S S S
150 38 Male Blood 5yrs + sepsis C.albicans S S S S S S S S S S
151 48 Male Br.wash 7yrs + Ca lung + Asp.fumigatus SDD S S S S S S S
152 20 Male blood 6yrs + AML C.albicans + R R R R R R S R R S
153 62 Male sputum 7yrs + Ca sigmoid colon NG
154 38 Male pl.fluid 8yrs + Ca lung NG
155 40 Male sputum 4yrs + Ca stomach with liver metastasis NG
156 62 Male sputum 12yrs + Ca ceacum NG
157 14 Male sputum 2yrs + Rtfemur osteosarcoma NG
158 69 Male sputum 15yrs + Ca sigmoid colon NG
159 15 Male pl.fluid 1yr + Lt tibial osteosarcoma pleural effusion NG
160 60 Male sputum 10yrs + Ca lung NG
161 31 Male Gastric lavage 4yrs + oesophageal candidiasis dysphagia, NEUTROPENIA NG
162 51 Male urine 3yrs + UTI C.albicans SDD SDD SDD S S S S S S S
163 62 Male sputum 12yrs + Ca lung NG
164 45 Male sputum 2yrs + Ca gall bladder & liver metastasis NG
165 30 Male ascitic fluid 3yrs + Ca ascending colon NG
166 32 Male pl.fluid 5yrs + NHL NG
167 30 Male sputum 5yrs + pneumonia CMV NG
168 42 Male sputum 7yrs + MDS NG
169 31 Male Gastric lavage 6yrs + esophageal candidiasis dysphagia C.albicans S S S S S S S S S S
170 33 Male urine 6yrs + UTI CMV NG
171 40 Male Gastric lavage 7yrs + esophageal candidiasis + C.albicans S S S S S S S S S S
172 28 Male CSF 4yrs + meningitis NG
173 45 Male CSF 5yrs + meningitis NG
174 35 Male palatal scraping 3yrs + mucormycosis NG
175 27 Female CSF 3yrs + meningitis NG
176 45 Male CSF 7yrs + meningitis + Cryptococcal sp S S S S S S S
177 20 Female CSF 2yrs + meningitis NG
178 45 Male CSF 6yrs + meningitis NG
179 55 Male CSF 8yrs + meningitis NG
180 39 Male CSF 6yrs + meningitis + Cryptococcal sp S S S S S S S
181 70 Male CSF 12yrs + meningitis NG
182 14 Female CSF 2yrs + meningitis NG
183 56 Female palatal scraping 6yrs + mucormycosis NG
184 60 Female Gastric lavage 12yrs + esophageal candidiasis NG
185 32 Female CSF 4yrs + meningitis NG
186 38 Female CSF 5yrs + meningitis + Cryptococcal sp S S S S S S S
187 56 Male CSF 6yrs + meningitis NG
188 35 Female CSF 5yrs + meningitis NG
189 33 Male CSF 3yrs + meningitis + Cryptococcal sp + S S S S S S S
190 34 Male CSF 3yrs + meningitis NG
191 17 Male CSF 5yrs + meningitis NG
192 21 Male sputum 5yrs + AML & PNEUMONIA NG
193 21 Male sputum 6yrs + AML RT ul consolidation NG
194 35 Male CSF 5yrs + meningitis NG
195 22 Female graft abscess + PUO HSV NG
196 40 Female sputum 7yrs + AML & PNEUMONIA NG
197 21 Female sputum 5yrs + ALL + + Fusarium sp R R R R S R R S
198 17 Male sputum 2yrs + CML & pneumonia NG
199 55 Female BAL 8yrs + MDS & pneumonia NG
200 70 Male FNAC debriment 15yrs + Mucormycosis of Rt palate NG
